<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Mol Neurobiol</journal-id><journal-id journal-id-type="iso-abbrev">Cell Mol Neurobiol</journal-id><journal-id journal-id-type="pmc-domain-id">4635</journal-id><journal-id journal-id-type="pmc-domain">cmneuro</journal-id><journal-title-group><journal-title>Cellular and Molecular Neurobiology</journal-title></journal-title-group><issn pub-type="ppub">0272-4340</issn><issn pub-type="epub">1573-6830</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11129978</article-id><article-id pub-id-type="pmcid-ver">PMC11129978.2</article-id><article-id pub-id-type="pmcaid">11129978</article-id><article-id pub-id-type="pmcaiid">11407163</article-id><article-id pub-id-type="pmid">38801645</article-id><article-id pub-id-type="doi">10.1007/s10571-024-01466-5</article-id><article-id pub-id-type="publisher-id">1466</article-id><article-version article-version-type="pmc-version">2</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>A Pharmacogenomics-Based In Silico Investigation of Opioid Prescribing in Post-operative Spine Pain Management and Personalized Therapy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7842-2914</contrib-id><name name-style="western"><surname>Lewandrowski</surname><given-names initials="KU">Kai-Uwe</given-names></name><address><email>business@tucsonspine.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8048-9587</contrib-id><name name-style="western"><surname>Sharafshah</surname><given-names initials="A">Alireza</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4438-7118</contrib-id><name name-style="western"><surname>Elfar</surname><given-names initials="J">John</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7654-5507</contrib-id><name name-style="western"><surname>Schmidt</surname><given-names initials="SL">Sergio Luis</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6727-803X</contrib-id><name name-style="western"><surname>Blum</surname><given-names initials="K">Kenneth</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wetzel</surname><given-names initials="FT">Franklin Todd</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><aff id="Aff1"><label>1</label>Division of Personalized Pain Therapy Research &amp; Education, Center for Advanced Spine Care of Southern Arizona, Arizona, USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.442116.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0404 9258</institution-id><institution>Department of Orthopaedics, </institution><institution>Fundaci&#243;n Universitaria Sanitas and Member of Colombian National Academy of Medicine, </institution></institution-wrap>Bogot&#225;, DC Colombia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04tec8z30</institution-id><institution-id institution-id-type="GRID">grid.467095.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2237 7915</institution-id><institution>Department of Orthopedics, </institution><institution>Doctor honoris causa Hospital Universit&#225;rio Gaffree Guinle Universidade Federal do Estado do Rio de Janeiro, and Member of the Brazilian National Academy of Medicine, </institution></institution-wrap>Rio de Janeiro, Brazil </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ptbrd12</institution-id><institution-id institution-id-type="GRID">grid.411874.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0571 1549</institution-id><institution>Cellular and Molecular Research Center, School of Medicine, </institution><institution>Guilan University of Medical Sciences, </institution></institution-wrap>Rasht, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.134563.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2168 186X</institution-id><institution>Department of Orthopaedics and Sports Medicine, </institution><institution>University of Arizona College of Medicine, </institution></institution-wrap>Tucson, AZ USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.8536.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2294 473X</institution-id><institution>Department of Neurology, </institution><institution>Federal University of Rio de Janeiro (UNIRIO), University Hospital, </institution></institution-wrap>Rua Mariz e Barros 750, Tijuca, Rio de Janeiro, RJ Brazil </aff><aff id="Aff7"><label>7</label>Division of Nutrigenomics, SpliceGen, Therapeutics, Inc., Austin, TX 78701 USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04qk6pt94</institution-id><institution-id institution-id-type="GRID">grid.268333.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7937</institution-id><institution>Department of Psychiatry, </institution><institution>Wright State University Boonshoft School of Medicine, </institution></institution-wrap>Dayton, OH 45435 USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05167c961</institution-id><institution-id institution-id-type="GRID">grid.268203.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0455 5679</institution-id><institution>Division of Addiction Research &amp; Education, Center for Sports, Exercise, &amp; Mental Health, </institution><institution>Western University Health Sciences, </institution></institution-wrap>Pomona, CA 91766 USA </aff><aff id="Aff10"><label>10</label>The Kenneth Blum Behavioral &amp; Neurogenetic Institute, LLC., Austin, TX 78701 USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.427850.c</institution-id><institution>Department of Orthopaedic Surgery &amp; Sports Medicine, </institution><institution>Director of Musculoskeletal Services Bassett Healthcare Network 1 Atwell Road, </institution></institution-wrap>Cooperstown, NY 13326 USA </aff><aff id="Aff12"><label>12</label>Center for Advanced Spine Care of Southern Arizona, 4787 E Camp Lowell Drive, Tucson, USA </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>44</volume><issue-id pub-id-type="pmc-issue-id">470646</issue-id><elocation-id>47</elocation-id><history><date date-type="received"><day>7</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>29</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-06 00:25:39.487"><day>06</day><month>03</month><year>2025</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">11129978</article-id><article-id pub-id-type="doi">10.1007/s10571-024-01466-5</article-id><article-version>1</article-version><pub-date><day>27</day><month>05</month><year>2024</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">11407163</article-id><article-id pub-id-type="doi">10.1007/s10571-024-01466-5</article-id><article-version>2</article-version><pub-date><day>27</day><month>05</month><year>2024</year></pub-date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10571_2024_Article_1466.pdf"/><abstract id="Abs1"><sec><title>Abstract</title><p id="Par1">Considering the variability in individual responses to opioids and the growing concerns about opioid addiction, prescribing opioids for postoperative pain management after spine surgery presents significant challenges. Therefore, this study undertook a novel pharmacogenomics-based in silico investigation of FDA-approved opioid medications. The DrugBank database was employed to identify all FDA-approved opioids. Subsequently, the PharmGKB database was utilized to filter through all variant annotations associated with the relevant genes. In addition, the dpSNP (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/snp/">https://www.ncbi.nlm.nih.gov/snp/</ext-link>), a publicly accessible repository, was used. Additional analyses were conducted using STRING-MODEL (version 12), Cytoscape (version 3.10.1), miRTargetLink.2, and NetworkAnalyst (version 3). The study identified 125 target genes of FDA-approved opioids, encompassing 7019 variant annotations. Of these, 3088 annotations were significant and pertained to 78 genes. During variant annotation assessments (VAA), 672 variants remained after filtration. Further in-depth filtration based on variant functions yielded 302 final filtered variants across 56 genes. The Monoamine GPCRs pathway emerged as the most significant signaling pathway. Protein&#8211;protein interaction (PPI) analysis revealed a fully connected network comprising 55 genes. Gene&#8211;miRNA Interaction (GMI) analysis of these 55 candidate genes identified miR-16-5p as a pivotal miRNA in this network. Protein&#8211;Drug Interaction (PDI) assessment showed that multiple drugs, including Ibuprofen, Nicotine, Tramadol, Haloperidol, Ketamine, <sc>l</sc>-Glutamic Acid, Caffeine, Citalopram, and Naloxone, had more than one interaction. Furthermore, Protein&#8211;Chemical Interaction (PCI) analysis highlighted that ABCB1, BCL2, CYP1A2, KCNH2, PTGS2, and DRD2 were key targets of the proposed chemicals. Notably, 10 chemicals, including carbamylhydrazine, tetrahydropalmatine, Terazosin, beta-methylcholine, rubimaillin, and quinelorane, demonstrated dual interactions with the aforementioned target genes. This comprehensive review offers multiple strong, evidence-based in silico findings regarding opioid prescribing in spine pain management, introducing 55 potential genes. The insights from this report can be applied in exome analysis as a pharmacogenomics (PGx) panel for pain susceptibility, facilitating individualized opioid prescribing through genotyping of related variants. The article also points out that African Americans represent an important group that displays a high catabolism of opioids and suggest the need for a personalized therapeutic approach based on genetic information.</p></sec><sec><title>Graphical Abstract</title><p>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO11" orientation="portrait" xlink:href="10571_2024_1466_Figa_HTML.jpg"/>
</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Pharmacogenomics</kwd><kwd>Opioid</kwd><kwd>Spine pain management</kwd><kwd>Variant</kwd><kwd>Drug</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The United States has been grappling with a concerning rise in issues related to prescription misuse, opioid use disorder, and fatal overdoses (El Ibrahimi et al. <xref ref-type="bibr" rid="CR25">2023</xref>; Wang et al. <xref ref-type="bibr" rid="CR74">2023</xref>). Over two decades, from 1999 to 2020, the country witnessed a staggering toll of over 263,000 lives lost due to overdoses linked to prescription opioids (Aaron <xref ref-type="bibr" rid="CR1">2023</xref>). This distressing figure represents a nearly fivefold increase in overdose deaths involving prescription opioids from 1999 to 2020 (B&#246;ttcher et al. <xref ref-type="bibr" rid="CR8">2023</xref>). The root of this crisis can be traced back to the 1990s, a period when the volume of opioids being prescribed to patients started to escalate (Friedman et al. <xref ref-type="bibr" rid="CR29">2020</xref>). Unfortunately, as the prescription quantities of opioids surged, so did the incidents of overdoses and fatalities stemming from these medications. Despite this surge in opioid prescriptions for pain management, there has been no corresponding alteration in the amount of pain reported by the American populace (Piper et al. <xref ref-type="bibr" rid="CR58">2018</xref>).</p><p id="Par3">The shift in medical practice has been partially ascribed to misleading information disseminated by pharmaceutical companies, who erroneously downplayed the risk of addiction associated with certain opioid pain relievers (Sarpatwari et al. <xref ref-type="bibr" rid="CR63">2017</xref>). This deceit had an effect since the truth regarding the highly addictive potential of these drugs recently became known (Meier <xref ref-type="bibr" rid="CR50">2003</xref>, <xref ref-type="bibr" rid="CR51">2018</xref>; Posner <xref ref-type="bibr" rid="CR59">2021</xref>).</p><p id="Par4">By then, many of these opioids had already been misused, abused, or diverted. Concurrently, the American Pain Society introduced the notion of pain as the &#8220;fifth vital sign,&#8221; advocating for its evaluation and treatment at par with traditional vital signs such as temperature, blood pressure, respiratory rate, and heart rate (Krauss et al. <xref ref-type="bibr" rid="CR40">2021</xref>). This concept gained traction in 2001 with the endorsement by the Joint Commission, placing pain management practices under closer scrutiny (Scher et al. <xref ref-type="bibr" rid="CR64">2018</xref>).</p><p id="Par5">2020 saw a grim average of 44 deaths daily due to prescription opioid overdoses, culminating in over 16,000 fatalities (Wilson et al. <xref ref-type="bibr" rid="CR76">2020</xref>). Almost a quarter (24%) of all deaths due to overdoses that year were related to prescription opioids; this suggests a 16% increase in prescription opioid-related morbidity between 2019 and 2020. Post-surgical pain management often marks patients' initial exposure to opioids, consequently posing a documented risk for chronic opioid dependence among opioid-na&#239;ve individuals. Alarmingly, around 70% of those using prescription opioids acquire them through diversion, frequently via legitimate prescriptions of friends and family (Krauss et al. <xref ref-type="bibr" rid="CR40">2021</xref>). Many surgeons, including orthopedic specialists who are ranked as the third-highest opioid prescribers, administer opioids to control postoperative pain. However, miscalculations in assessing the extent of postoperative pain can lead to excessive opioid prescriptions after surgery, inadvertently contributing to the surplus of unused pills that can be diverted (Orosz et al. <xref ref-type="bibr" rid="CR56">2022</xref>). The following distinct challenges are common in pain management of spine patients:</p><p id="Par6">Substantial postoperative opioid needs have been associated with spine surgeries, as evidenced by recent studies encompassing various orthopedic and non-orthopedic elective procedures (Wyles et al. <xref ref-type="bibr" rid="CR78">2021</xref>).</p><p id="Par7">Data extrapolated from the Global Burden of Disease, Injuries, and Risk Factors Study spanning 1990 to 2017 identifies low back pain as a leading cause of global disability, persistently ranking among the top five worldwide (Wu et al. <xref ref-type="bibr" rid="CR77">2020</xref>).</p><p id="Par8">Many patients are prescribed opioids before consulting a spine surgeon, rendering them opioid-experienced, consequently heightening the risk of opioid misuse, abuse, and dependency (Cram et al. <xref ref-type="bibr" rid="CR19">2019</xref>).</p><p id="Par9">The population of the United States is living longer, and undergoing more spine surgery. For example, between 2020 and 2040, surgical procedures for Anterior Cervical Discectomy and Fusion (ACDF) are anticipated to grow by 13.3% (from 153,288 to 173,699 procedures), while Posterior Cervical Discectomy and Fusion (PCDF) surgeries are expected to see a 19.3% increase (from 29,620 to 35,335 procedures). The most significant growth for ACDF is forecasted in the 45&#8211;54 age bracket (from 42,077 to 49,827) and the 75&#8211;84 age bracket (from 8065 to 14,862). For PCDF, the 75&#8211;84 age bracket is projected to experience the most substantial rise (from 3710 to 6836). With the demographic shift toward an older population, slight upticks are also predicted in the over-85 age group for ACDF (from 858 to 1847) and PCDF (from 730 to 1573) (Neifert et al. <xref ref-type="bibr" rid="CR55">2020</xref>).</p><p id="Par10">Despite the identification of specific predictors that influence patterns of opioid overuse, (Dasgupta et al. <xref ref-type="bibr" rid="CR21">2018</xref>) such as prior opioid use, surgery type, patient age, body mass index (BMI), diagnoses of depression or anxiety, length of hospital stay, and pain scores at discharge, there is a notable absence of precise pharmacogenetic parameters in preoperative protocols. The integration of genetic factors into these protocols could be instrumental in preparing patients for postoperative pain and in determining the most effective pain management strategies. Given that opioids are among the top 30 medications with significant pharmacogenetic implications, the prospect of leveraging genetic information to guide perioperative and postoperative pain management is promising, yet its practical application remains limited (Sadhasivam and Chidambaran <xref ref-type="bibr" rid="CR62">2012</xref>). In this context, a patient's genetic profile related to opioid susceptibility and responsiveness could potentially replace traditional pain management methods, reducing the risks associated with opioid use and identifying more effective treatment alternatives (Manworren <xref ref-type="bibr" rid="CR47">2015</xref>). The most potential annotations related to the candidate genes were extracted, refined, and presented in detail (Gene, RS ID, Function, Related Drug, Genotype-phenotype associations) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>The most potential variant annotations of 55 candidate genes with structural functions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Gene</th><th align="left" colspan="1" rowspan="1">Variant</th><th align="left" colspan="1" rowspan="1">Function</th><th align="left" colspan="1" rowspan="1">Drugs</th><th align="left" colspan="1" rowspan="1">Association</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ABCB1</td><td align="left" colspan="1" rowspan="1">rs2229107</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Phenytoin</td><td align="left" colspan="1" rowspan="1">Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype TT</td></tr><tr><td align="left" colspan="1" rowspan="1">ABCB1</td><td align="left" colspan="1" rowspan="1">rs9282564</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Tacrolimus</td><td align="left" colspan="1" rowspan="1">Genotypes CC&#8201;+&#8201;CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT</td></tr><tr><td align="left" colspan="1" rowspan="1">ADRA1A</td><td align="left" colspan="1" rowspan="1">rs1048101</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Disulfiram</td><td align="left" colspan="1" rowspan="1">Genotypes AA&#8201;+&#8201;AG is associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotype GG</td></tr><tr><td align="left" colspan="1" rowspan="1">ADRA2A</td><td align="left" colspan="1" rowspan="1">rs1800035</td><td align="left" colspan="1" rowspan="1">Missense/promoter</td><td align="left" colspan="1" rowspan="1">Dexmedetomidine</td><td align="left" colspan="1" rowspan="1">Genotypes CG&#8201;+&#8201;GG are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC</td></tr><tr><td align="left" colspan="1" rowspan="1">ADRB1</td><td align="left" colspan="1" rowspan="1">rs1801252</td><td align="left" colspan="1" rowspan="1">Missense/promoter</td><td align="left" colspan="1" rowspan="1">Verapamil</td><td align="left" colspan="1" rowspan="1">Genotypes AA&#8201;+&#8201;AG are associated with increased risk of Death when treated with verapamil in people with Coronary Artery Disease as compared to genotype GG</td></tr><tr><td align="left" colspan="1" rowspan="1">ADRB1</td><td align="left" colspan="1" rowspan="1">rs1801253</td><td align="left" colspan="1" rowspan="1">Missense/promoter</td><td align="left" colspan="1" rowspan="1">Carvedilol</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with increased improvement in left ventricular function (LVEF) when treated with carvedilol in people with Heart Failure as compared to genotype GG</td></tr><tr><td align="left" colspan="1" rowspan="1">ANKK1; DRD2</td><td align="left" colspan="1" rowspan="1">rs1800497</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Bupropion; naltrexone</td><td align="left" colspan="1" rowspan="1">Genotypes AA&#8201;+&#8201;AG are associated with increased response to bupropion and naltrexone in people with Obesity as compared to genotype GG</td></tr><tr><td align="left" colspan="1" rowspan="1">BCHE</td><td align="left" colspan="1" rowspan="1">rs1799807</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Succinylcholine</td><td align="left" colspan="1" rowspan="1">Allele C is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele T</td></tr><tr><td align="left" colspan="1" rowspan="1">BCHE</td><td align="left" colspan="1" rowspan="1">rs1803274</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Cocaine</td><td align="left" colspan="1" rowspan="1">Genotype TT is associated with Cocaine-Related Disorders when exposed to cocaine in as compared to genotypes CC&#8201;+&#8201;CT</td></tr><tr><td align="left" colspan="1" rowspan="1">BCL2</td><td align="left" colspan="1" rowspan="1">rs1800477</td><td align="left" colspan="1" rowspan="1">Missense/promoter</td><td align="left" colspan="1" rowspan="1">Interferons; ribavirin</td><td align="left" colspan="1" rowspan="1">Allele T is associated with increased frequency (about double) in non-responder patients compared with responder patients (HCV genotype 4) when treated with interferons and ribavirin in people with Hepatitis C, Chronic as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">CACNA1H</td><td align="left" colspan="1" rowspan="1">rs61734410</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Ethosuximide</td><td align="left" colspan="1" rowspan="1">Allele T is associated with decreased clinical benefit to ethosuximide in children with Epilepsy as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">CES1</td><td align="left" colspan="1" rowspan="1">rs114119971</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Methylphenidate</td><td align="left" colspan="1" rowspan="1">Genotype CG is associated with decreased dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG</td></tr><tr><td align="left" colspan="1" rowspan="1">CFTR</td><td align="left" colspan="1" rowspan="1">rs77010898</td><td align="left" colspan="1" rowspan="1">Missense/stop-gained</td><td align="left" colspan="1" rowspan="1">Ataluren</td><td align="left" colspan="1" rowspan="1">Allele A is associated with response to ataluren in children with Cystic Fibrosis as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">CHRNA3</td><td align="left" colspan="1" rowspan="1">rs3743075</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Nicotine</td><td align="left" colspan="1" rowspan="1">Allele T is associated with decreased severity of Tobacco Use Disorder due to nicotine in men as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">CHRNA3; CHRNA5</td><td align="left" colspan="1" rowspan="1">rs16969968</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Drugs used in nicotine dependence</td><td align="left" colspan="1" rowspan="1">Allele G is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder</td></tr><tr><td align="left" colspan="1" rowspan="1">CHRNA4</td><td align="left" colspan="1" rowspan="1">rs1044396</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Nicotine</td><td align="left" colspan="1" rowspan="1">Allele G is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP1B1</td><td align="left" colspan="1" rowspan="1">rs1056837</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Codeine; tramadol</td><td align="left" colspan="1" rowspan="1">Allele A is associated with decreased clinical benefit to codeine or tramadol in men with Pain as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP2D6</td><td align="left" colspan="1" rowspan="1">rs35742686</td><td align="left" colspan="1" rowspan="1">Frameshift</td><td align="left" colspan="1" rowspan="1">Hydrocodone; oxycodone</td><td align="left" colspan="1" rowspan="1">Allele DELT is associated with increased clinical benefit to hydrocodone or oxycodone in people with Pain as compared to allele T</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP2D6</td><td align="left" colspan="1" rowspan="1">CYP2D6*1; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*14; CYP2D6*21; CYP2D6*36; CYP2D6*41</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Tamoxifen</td><td align="left" colspan="1" rowspan="1">CYP2D6*4&#8201;+&#8201;*5&#8201;+&#8201;*10&#8201;+&#8201;*14&#8201;+&#8201;*21&#8201;+&#8201;*36&#8201;+&#8201;*41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6*1/*1</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP2D6</td><td align="left" colspan="1" rowspan="1">CYP2D6*1; CYP2D6*5; CYP2D6*17 rs28371706(T) rs16947(A)</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Codeine; debrisoquine; dextromethorphan; metoprolol</td><td align="left" colspan="1" rowspan="1">CYP2D6*5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6*17/*17&#8201;+&#8201;*1/*1</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP2D6</td><td align="left" colspan="1" rowspan="1">CYP2D6*1; CYP2D6*4; CYP2D6*9 (rs5030656; K281del)</td><td align="left" colspan="1" rowspan="1">Missense/deletion</td><td align="left" colspan="1" rowspan="1">Tramadol</td><td align="left" colspan="1" rowspan="1">CYP2D6*1/*4&#8201;+&#8201;*1/*9 (assigned as intermediate metabolizer genotype phenotype) are associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6*1/*1 (assigned as normal metabolizer genotype phenotype)</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP3A5</td><td align="left" colspan="1" rowspan="1">rs41303343</td><td align="left" colspan="1" rowspan="1">Frameshift</td><td align="left" colspan="1" rowspan="1">Tacrolimus</td><td align="left" colspan="1" rowspan="1">Allele A is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to allele del</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP3A7</td><td align="left" colspan="1" rowspan="1">rs2257401</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Tacrolimus</td><td align="left" colspan="1" rowspan="1">Allele C is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">DRD3</td><td align="left" colspan="1" rowspan="1">rs6280</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Risperidone</td><td align="left" colspan="1" rowspan="1">Genotypes CC&#8201;+&#8201;CT is associated with increased response to risperidone in children with Autistic Disorder as compared to genotype TT</td></tr><tr><td align="left" colspan="1" rowspan="1">GABRA2</td><td align="left" colspan="1" rowspan="1">rs279858</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Sevoflurane</td><td align="left" colspan="1" rowspan="1">Genotypes CC&#8201;+&#8201;CT are associated with decreased mean arterial pressure when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype TT</td></tr><tr><td align="left" colspan="1" rowspan="1">GP1BA</td><td align="left" colspan="1" rowspan="1">rs6065</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Aspirin</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with increased risk of aspirin resistance when treated with aspirin in healthy individuals as compared to genotypes CT&#8201;+&#8201;TT</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR2A</td><td align="left" colspan="1" rowspan="1">rs6314</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Antidepressants</td><td align="left" colspan="1" rowspan="1">Genotypes AG&#8201;+&#8201;GG are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR2C</td><td align="left" colspan="1" rowspan="1">rs6318</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Escitalopram</td><td align="left" colspan="1" rowspan="1">Allele C is associated with decreased Pain when treated with escitalopram in men with neuropathic pain as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">KCNH2</td><td align="left" colspan="1" rowspan="1">rs1137617</td><td align="left" colspan="1" rowspan="1">Missense/stop-gained</td><td align="left" colspan="1" rowspan="1">Calcium channel blockers; nitrendipine</td><td align="left" colspan="1" rowspan="1">Genotypes AA&#8201;+&#8201;AG are associated with increased reduction in blood pressure when treated with calcium channel blockers or nitrendipine in people with Essential hypertension as compared to genotype GG</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">rs1799971</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Ethanol; naltrexone</td><td align="left" colspan="1" rowspan="1">Genotypes AG&#8201;+&#8201;GG are associated with increased severity of intoxication when exposed to ethanol and naltrexone in healthy individuals as compared to genotype AA</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">rs1799972</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Cocaine; ethanol; nicotine</td><td align="left" colspan="1" rowspan="1">Genotype TT is associated with increased risk of Substance-Related Disorders due to cocaine, ethanol or nicotine in women as compared to genotypes CC&#8201;+&#8201;CT</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">rs540825</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Fentanyl</td><td align="left" colspan="1" rowspan="1">Allele T is associated with increased likelihood of Vomiting due to fentanyl in women with Pain, Postoperative as compared to allele A</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">rs562859</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Heroin</td><td align="left" colspan="1" rowspan="1">Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">rs62638690</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Cocaine; heroin</td><td align="left" colspan="1" rowspan="1">Allele T is associated with decreased likelihood of Cocaine-Related Disorders or Heroin Dependence due to cocaine or heroin as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">rs6912029</td><td align="left" colspan="1" rowspan="1">Missense/promoter</td><td align="left" colspan="1" rowspan="1">Cotinine</td><td align="left" colspan="1" rowspan="1">Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">rs677830</td><td align="left" colspan="1" rowspan="1">Missense/stop-gained</td><td align="left" colspan="1" rowspan="1">Acetaminophen/tramadol</td><td align="left" colspan="1" rowspan="1">Genotypes CT&#8201;+&#8201;TT is associated with increased likelihood of Constipation when treated with acetaminophen/tramadol in people with Pain, Postoperative as compared to genotype CC</td></tr><tr><td align="left" colspan="1" rowspan="1">PPARG</td><td align="left" colspan="1" rowspan="1">rs1801282</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Pioglitazone</td><td align="left" colspan="1" rowspan="1">Genotype CG is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC</td></tr><tr><td align="left" colspan="1" rowspan="1">PTGS1</td><td align="left" colspan="1" rowspan="1">rs5789</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Antiinflammatory agents, non-steroids</td><td align="left" colspan="1" rowspan="1">Allele C is associated with decreased likelihood of aspirin-induced asthma when exposed to Antiinflammatory agents, non-steroids in people with Asthma as compared to allele A</td></tr><tr><td align="left" colspan="1" rowspan="1">SLC6A2</td><td align="left" colspan="1" rowspan="1">rs5569</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Methylphenidate</td><td align="left" colspan="1" rowspan="1">Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA&#8201;+&#8201;AG</td></tr><tr><td align="left" colspan="1" rowspan="1">TLR4</td><td align="left" colspan="1" rowspan="1">rs4986791</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Prednisolone</td><td align="left" colspan="1" rowspan="1">Allele T is associated with decreased clinical benefit to prednisolone in children with Thrombocytopenia as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">TRPV1</td><td align="left" colspan="1" rowspan="1">rs8065080</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">Cannabinoids</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with increased clinical benefit to cannabinoids in people with Pain as compared to genotypes CT&#8201;+&#8201;TT</td></tr></tbody></table></table-wrap></p><p id="Par11">One potentially important tool may reside in a validated Genetic Addiction Risk Severity (GARS&#174;) test that measure risk polymorphisms across ten reward genes having heuristic value to predetermine high genetic risk for opioid dependence. It is important to consider the interaction of neurotransmitters and genes that control the release of dopamine in the Brain Reward Cascade (BRC). It is well-known that variations within the BRC, whether genetic or epigenetic, may predispose people to addictive behaviors and alter pain tolerance. The GARS, which is the first test to accurately predict vulnerability to pain, addiction, and other compulsive behaviors, is defined as Reward Deficiency Syndrome (RDS). Moreover, sensitivity to pain may reside in the mesolimbic projection system, where genetic polymorphisms are associated with a predisposition to pain vulnerability or tolerance. Blum&#8217;s laboratory statistically validated the GARS test in 74,566 case&#8211;control subjects with Alcohol Use Disorder (AUD). This analysis assessed the Hardy&#8211;Weinberg Equilibrium (HWE) of each single nucleotide polymorphism (SNP) in controls and cases. If available, the Pearson's <italic toggle="yes">&#967;</italic><sup>2</sup> test or Fisher's exact test was utilized for comparing the gender, genotype, and allele distributions. The statistical analyses found the OR, 95% CI for OR, and a post-risk for 8% estimation of the population's alcoholism prevalence showed a significant detection. The OR results indicated significance for COMT, OPRM1, DRD2, DRD3, DRD4, DAT1, and 5HTT at 5% (Blum et al. <xref ref-type="bibr" rid="CR7">2018</xref>, <xref ref-type="bibr" rid="CR3">2020</xref>, <xref ref-type="bibr" rid="CR4">2021</xref>; Blum et al. <xref ref-type="bibr" rid="CR5">2022a</xref>, <xref ref-type="bibr" rid="CR6">b</xref>; Blum et al. <xref ref-type="bibr" rid="CR5">2022a</xref>, <xref ref-type="bibr" rid="CR6">b</xref>; Fried et al. <xref ref-type="bibr" rid="CR28">2020</xref>; Moran et al. <xref ref-type="bibr" rid="CR54">2021</xref>; Bajaj et al. <xref ref-type="bibr" rid="CR2">2022</xref>; Dennen et al. <xref ref-type="bibr" rid="CR22">2022</xref>; Gondr&#233;-Lewis et al. <xref ref-type="bibr" rid="CR33">2022</xref>; Gupta et al. <xref ref-type="bibr" rid="CR34">2022</xref>; Vereczkei et al. <xref ref-type="bibr" rid="CR73">2022</xref>; Thanos et al. <xref ref-type="bibr" rid="CR70">2023a</xref>, <xref ref-type="bibr" rid="CR71">b</xref>; Thanos et al. <xref ref-type="bibr" rid="CR70">2023a</xref>, <xref ref-type="bibr" rid="CR71">b</xref>). Consequently, this study aimed to explore the most effective pharmacogenomic approach to managing spinal pain in postoperative patients by analyzing potential actionable genetic variants associated with FDA-approved drugs targeting specific receptors, that is, the genes themselves (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>The most potential variant annotations of 55 candidate genes with regulatory functions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Gene</th><th align="left" colspan="1" rowspan="1">Function</th><th align="left" colspan="1" rowspan="1">Variant</th><th align="left" colspan="1" rowspan="1">Drugs</th><th align="left" colspan="1" rowspan="1">Association</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ABCB1</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs12535512</td><td align="left" colspan="1" rowspan="1">Risperidone</td><td align="left" colspan="1" rowspan="1">Genotypes CC&#8201;+&#8201;CT are not associated with response to risperidone in people with Schizophrenia as compared to genotype TT</td></tr><tr><td align="left" colspan="1" rowspan="1">ABCB1</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs3789243</td><td align="left" colspan="1" rowspan="1">Antiepileptics</td><td align="left" colspan="1" rowspan="1">Allele G is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy</td></tr><tr><td align="left" colspan="1" rowspan="1">ADORA1</td><td align="left" colspan="1" rowspan="1">CTCF</td><td align="left" colspan="1" rowspan="1">rs16851030</td><td align="left" colspan="1" rowspan="1">Aspirin</td><td align="left" colspan="1" rowspan="1">Genotype TT is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotypes CC&#8201;+&#8201;CT</td></tr><tr><td align="left" colspan="1" rowspan="1">ADORA2A</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs3761422</td><td align="left" colspan="1" rowspan="1">Methotrexate</td><td align="left" colspan="1" rowspan="1">Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">ADRA2A</td><td align="left" colspan="1" rowspan="1">Promoter/CTCF</td><td align="left" colspan="1" rowspan="1">rs1800544</td><td align="left" colspan="1" rowspan="1">Dexmedetomidine</td><td align="left" colspan="1" rowspan="1">Genotype GG is associated with decreased dose of dexmedetomidine in people with surgery as compared to genotypes CC&#8201;+&#8201;CG</td></tr><tr><td align="left" colspan="1" rowspan="1">CALM1</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs12885713</td><td align="left" colspan="1" rowspan="1">Cyclosporine</td><td align="left" colspan="1" rowspan="1">Allele T is associated with increased response to cyclosporine in people with Psoriasis as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">CAT</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs1001179</td><td align="left" colspan="1" rowspan="1">Ethanol</td><td align="left" colspan="1" rowspan="1">Allele T is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">CHRM1</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs2075748</td><td align="left" colspan="1" rowspan="1">Clozapine</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with decreased dose of clozapine in people with Schizophrenia as compared to genotypes CT&#8201;+&#8201;TT</td></tr><tr><td align="left" colspan="1" rowspan="1">CHRNA3</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs7170068</td><td align="left" colspan="1" rowspan="1">Cotinine</td><td align="left" colspan="1" rowspan="1">Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">CHRNA4</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs2236196</td><td align="left" colspan="1" rowspan="1">Nicotine</td><td align="left" colspan="1" rowspan="1">Allele G is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A</td></tr><tr><td align="left" colspan="1" rowspan="1">CHRNB2</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs2072658</td><td align="left" colspan="1" rowspan="1">Nicotine</td><td align="left" colspan="1" rowspan="1">Genotype AG is associated with increased response to nicotine in people with daily smoking as compared to genotype GG</td></tr><tr><td align="left" colspan="1" rowspan="1">CHRNB4</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs10851907</td><td align="left" colspan="1" rowspan="1">Cotinine</td><td align="left" colspan="1" rowspan="1">Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">CNR1</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs806368</td><td align="left" colspan="1" rowspan="1">Cocaine</td><td align="left" colspan="1" rowspan="1">Allele C is associated with decreased risk of Cocaine-Related Disorders when exposed to cocaine as compared to allele T</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP1A2</td><td align="left" colspan="1" rowspan="1">CTCF</td><td align="left" colspan="1" rowspan="1">rs2069526</td><td align="left" colspan="1" rowspan="1">Escitalopram</td><td align="left" colspan="1" rowspan="1">Allele G is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele T</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP2D6</td><td align="left" colspan="1" rowspan="1">Splicing</td><td align="left" colspan="1" rowspan="1">CYP2D6*1; CYP2D6*1xN; CYP2D6*3; CYP2D6*4; CYP2D6*6</td><td align="left" colspan="1" rowspan="1">Codeine</td><td align="left" colspan="1" rowspan="1">CYP2D6*1xN/*1 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP3A5</td><td align="left" colspan="1" rowspan="1">Splicing/enhancer</td><td align="left" colspan="1" rowspan="1">rs776746</td><td align="left" colspan="1" rowspan="1">Tacrolimus</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT&#8201;+&#8201;TT</td></tr><tr><td align="left" colspan="1" rowspan="1">DRD2</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs12364283</td><td align="left" colspan="1" rowspan="1">Amphetamine</td><td align="left" colspan="1" rowspan="1">Genotype AA is associated with decreased stop reaction time when treated with amphetamine in healthy individuals as compared to genotypes AG&#8201;+&#8201;GG</td></tr><tr><td align="left" colspan="1" rowspan="1">DRD2</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs4436578</td><td align="left" colspan="1" rowspan="1">Clozapine; olanzapine; risperidone</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with increased risk of body weight gain when treated with clozapine, olanzapine or risperidone in people with Schizophrenia</td></tr><tr><td align="left" colspan="1" rowspan="1">DRD2</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs1799732</td><td align="left" colspan="1" rowspan="1">Ethanol</td><td align="left" colspan="1" rowspan="1">Genotype GG is associated with increased severity of Alcoholism due to ethanol as compared to genotypes G/del&#8201;+&#8201;del/del</td></tr><tr><td align="left" colspan="1" rowspan="1">EGF</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs4444903</td><td align="left" colspan="1" rowspan="1">Cetuximab</td><td align="left" colspan="1" rowspan="1">Genotype AA is associated with increased survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotypes AG&#8201;+&#8201;GG</td></tr><tr><td align="left" colspan="1" rowspan="1">GABRA2</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs11503014</td><td align="left" colspan="1" rowspan="1">Cocaine</td><td align="left" colspan="1" rowspan="1">Allele G is associated with increased severity of Cocaine-Related Disorders due to cocaine as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">GRIN1</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs1126442</td><td align="left" colspan="1" rowspan="1">Methamphetamine</td><td align="left" colspan="1" rowspan="1">Genotype GG is associated with increased risk of Psychotic Disorders when exposed to methamphetamine in men with methamphetamine dependence as compared to genotypes AA&#8201;+&#8201;AG</td></tr><tr><td align="left" colspan="1" rowspan="1">GRIN2B</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs2058878</td><td align="left" colspan="1" rowspan="1">Acamprosate</td><td align="left" colspan="1" rowspan="1">Allele A is associated with increased response to acamprosate in people with Alcoholism as compared to allele T</td></tr><tr><td align="left" colspan="1" rowspan="1">GRIN2B</td><td align="left" colspan="1" rowspan="1">Splicing/promoter</td><td align="left" colspan="1" rowspan="1">rs1019385</td><td align="left" colspan="1" rowspan="1">Valproic acid</td><td align="left" colspan="1" rowspan="1">Genotype AC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotype AA</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR1B</td><td align="left" colspan="1" rowspan="1">CTCF</td><td align="left" colspan="1" rowspan="1">rs9361235</td><td align="left" colspan="1" rowspan="1">Fluoxetine</td><td align="left" colspan="1" rowspan="1">Genotypes CC&#8201;+&#8201;TT is associated with increased response to fluoxetine in children with Depressive Disorder, Major as compared to genotype CT</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR1B</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs130058</td><td align="left" colspan="1" rowspan="1">Clomipramine; liothyronine; lithium; nefazodone; venlafaxine</td><td align="left" colspan="1" rowspan="1">Allele A is associated with decreased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine in people with Depression as compared to allele T</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR1B</td><td align="left" colspan="1" rowspan="1">Promoter/CTCF</td><td align="left" colspan="1" rowspan="1">rs11568817</td><td align="left" colspan="1" rowspan="1">Escitalopram</td><td align="left" colspan="1" rowspan="1">Genotypes AC&#8201;+&#8201;CC is associated with increased risk of adverse cognitive effects when treated with escitalopram in people with Anxiety Disorders as compared to genotype AA</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR1B</td><td align="left" colspan="1" rowspan="1">Promoter/CTCF</td><td align="left" colspan="1" rowspan="1">rs6296</td><td align="left" colspan="1" rowspan="1">Citalopram</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with increased risk of agitation when treated with citalopram in children with Anxiety Disorders or Depressive Disorder, Major as compared to genotypes CG&#8201;+&#8201;GG</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR2A</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs2770296</td><td align="left" colspan="1" rowspan="1">Bupropion</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT&#8201;+&#8201;TT</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR2A</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs6311</td><td align="left" colspan="1" rowspan="1">Citalopram; escitalopram; fluoxetine; paroxetine; sertraline</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with increased likelihood of Sexual Dysfunctions, Psychological when treated with citalopram, escitalopram, fluoxetine, paroxetine or sertraline in people with Depression as compared to genotypes CT&#8201;+&#8201;TT</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR2A</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs6313</td><td align="left" colspan="1" rowspan="1">Antidepressants</td><td align="left" colspan="1" rowspan="1">Genotype GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA&#8201;+&#8201;AG</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR2C</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs9698290</td><td align="left" colspan="1" rowspan="1">Risperidone</td><td align="left" colspan="1" rowspan="1">Genotype TT is associated with increased response to risperidone in women with Schizophrenia as compared to genotypes CC&#8201;+&#8201;CT</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR3A</td><td align="left" colspan="1" rowspan="1">Promoter/CTCF</td><td align="left" colspan="1" rowspan="1">rs1062613</td><td align="left" colspan="1" rowspan="1">Clozapine</td><td align="left" colspan="1" rowspan="1">Allele C is associated with increased response to clozapine in people with Schizophrenia as compared to allele T</td></tr><tr><td align="left" colspan="1" rowspan="1">HTR7</td><td align="left" colspan="1" rowspan="1">Open chromatin</td><td align="left" colspan="1" rowspan="1">rs1935349</td><td align="left" colspan="1" rowspan="1">Atorvastatin; pravastatin; simvastatin</td><td align="left" colspan="1" rowspan="1">Allele T is associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRK1</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs1051660</td><td align="left" colspan="1" rowspan="1">Morphine</td><td align="left" colspan="1" rowspan="1">Allele A is associated with decreased dose of morphine in people with Pain as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRL1</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs6090041</td><td align="left" colspan="1" rowspan="1">Opioids</td><td align="left" colspan="1" rowspan="1">Allele G is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele A</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">CTCF/enhancer</td><td align="left" colspan="1" rowspan="1">rs2281617</td><td align="left" colspan="1" rowspan="1">Amphetamine</td><td align="left" colspan="1" rowspan="1">Genotype CC is associated with increased Euphoric and Energetic after amphetamine (10&#160;mg) when exposed to amphetamine in healthy individuals as compared to genotypes CT&#8201;+&#8201;TT</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs10485058</td><td align="left" colspan="1" rowspan="1">Methadone</td><td align="left" colspan="1" rowspan="1">Genotype AA is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes AG&#8201;+&#8201;GG</td></tr><tr><td align="left" colspan="1" rowspan="1">OPRM1</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs9397685</td><td align="left" colspan="1" rowspan="1">Fentanyl</td><td align="left" colspan="1" rowspan="1">Genotype AG is associated with decreased severity of Nausea or Vomiting due to fentanyl in people with Pain, Postoperative as compared to genotype AA</td></tr><tr><td align="left" colspan="1" rowspan="1">PPARA</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs4253778</td><td align="left" colspan="1" rowspan="1">Atenolol; Beta Blocking Agents; carvedilol; metoprolol</td><td align="left" colspan="1" rowspan="1">Genotype GG is associated with decreased cardiac rehospitalization when treated with atenolol, Beta Blocking Agents, carvedilol or metoprolol in people with Acute coronary syndrome as compared to genotypes CC&#8201;+&#8201;CG</td></tr><tr><td align="left" colspan="1" rowspan="1">PPARG</td><td align="left" colspan="1" rowspan="1">Open chromatin</td><td align="left" colspan="1" rowspan="1">rs3856806</td><td align="left" colspan="1" rowspan="1">Aspirin</td><td align="left" colspan="1" rowspan="1">Genotype TT is associated with increased risk of aspirin hypersensitivity when treated with aspirin in people with Asthma as compared to genotypes CC&#8201;+&#8201;CT</td></tr><tr><td align="left" colspan="1" rowspan="1">PTGS1</td><td align="left" colspan="1" rowspan="1">Promoter</td><td align="left" colspan="1" rowspan="1">rs10306114</td><td align="left" colspan="1" rowspan="1">Aspirin</td><td align="left" colspan="1" rowspan="1">Allele G is associated with increased risk of non-response to aspirin when treated with aspirin in people with Coronary Artery Disease as compared to genotype AA</td></tr><tr><td align="left" colspan="1" rowspan="1">SCN2A</td><td align="left" colspan="1" rowspan="1">Splicing</td><td align="left" colspan="1" rowspan="1">rs17183814</td><td align="left" colspan="1" rowspan="1">Carbamazepine; phenobarbital; phenytoin; valproic acid</td><td align="left" colspan="1" rowspan="1">Allele A is associated with resistance to carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">SLC6A2</td><td align="left" colspan="1" rowspan="1">CTCF</td><td align="left" colspan="1" rowspan="1">rs2242446</td><td align="left" colspan="1" rowspan="1">3, 4-Methylenedioxymethamphetamine</td><td align="left" colspan="1" rowspan="1">Genotype TT are associated with decreased response to 3, 4-methylenedioxymethamphetamine as compared to genotypes CC&#8201;+&#8201;CT</td></tr><tr><td align="left" colspan="1" rowspan="1">SLC6A2</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs12708954</td><td align="left" colspan="1" rowspan="1">Atomoxetine</td><td align="left" colspan="1" rowspan="1">Allele A is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C</td></tr><tr><td align="left" colspan="1" rowspan="1">SLC6A4</td><td align="left" colspan="1" rowspan="1">CTCF</td><td align="left" colspan="1" rowspan="1">rs25531</td><td align="left" colspan="1" rowspan="1">Venlafaxine</td><td align="left" colspan="1" rowspan="1">Genotype TT is associated with increased reduction in HAM-A when treated with venlafaxine in people with Anxiety Disorders as compared to genotypes CC&#8201;+&#8201;CT</td></tr><tr><td align="left" colspan="1" rowspan="1">SLC6A4</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs2066713</td><td align="left" colspan="1" rowspan="1">Ethanol</td><td align="left" colspan="1" rowspan="1">Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G</td></tr><tr><td align="left" colspan="1" rowspan="1">TACR1</td><td align="left" colspan="1" rowspan="1">Enhancer</td><td align="left" colspan="1" rowspan="1">rs735668</td><td align="left" colspan="1" rowspan="1">Opioids</td><td align="left" colspan="1" rowspan="1">Genotype AA is associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes AC&#8201;+&#8201;CC</td></tr></tbody></table><table-wrap-foot><p>CTCF refers to CCCTC-binding site which is a negative regulatory for expression and enhancer is a positive regulatory binding site for transcription factors</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec2"><title>Methods</title><p id="Par12">This study designed a bioinformatics strategy first and then reviewed the PubMed data for the keywords such as opioids, spine surgery, spine pain, pharmacogenomics, and personalized medicine. These keywords were considered the main focus of publications filtering the papers containing opioid use in spine surgery for example. To reach a precise archive of related researches, some studies were excluded from this review due to the lack of if they failed to highlight how opioids may impact spine pain management. Thus, this investigation is divided into two main categorizations; in sillico computational database analysis investigations and systematic review of the literature. The publically available and accessible dpSNP database was searched (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/snp/">https://www.ncbi.nlm.nih.gov/snp/</ext-link>) for our reference variants.</p><sec id="Sec3"><title>In Silico Methods</title><p id="Par13">Documenting the DrugBank results of approved drugs having a role in opioid addiction, commonly used drugs such as methadone, morphine, and amphetamine were selected. The database was search for targets associated with these drugs. Following this step, all the targets were merged and duplicated targets were omitted. The in silico analyses carried out in the current study included Variant annotation assessment (VAA) by PharmGKB (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</ext-link>), signaling pathways (Cytoscape ver. 3.10.1), protein&#8211;protein interactions (PPI) by STRING-MODEL (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link>), Gene&#8211;miRNA interactions (GMI) by miRTargetLink2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ccb-compute.cs.uni-saarland.de/mirtargetlink2">https://ccb-compute.cs.uni-saarland.de/mirtargetlink2</ext-link>), and Protein&#8211;drug interactions (PDI) and Protein&#8211;Chemical Interactions (PCIs) by NetworkAnalyst (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.networkanalyst.ca/NetworkAnalyst/">https://www.networkanalyst.ca/NetworkAnalyst/</ext-link>). The results of all aforementioned interactions are described in the various sub-sections of the &#8220;Results&#8221; section.</p></sec></sec><sec id="Sec4"><title>Results</title><sec id="Sec5"><title>Protein&#8211;Protein Interactions (PPI)</title><p id="Par14">A large network of 126 opioid targets was extracted by STRING MODEL via the DrugBank search. Almost all of the proteins were connected in this network except CCKBR. Hence, further analysis was done with the 125 remaining genes. PPI enrichment <italic toggle="yes">p</italic>-value was lower than 1.0e&#8722;16. The other molecularly-demonstrated fully-connected targets were selected for further analyses (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>STRING-MODEL of 126 extracted targets of FDA-approved drugs from DrugBank visualized by a PPI enrichment <italic toggle="yes">p</italic>-value lower than 1.0e&#8722;16</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="10571_2024_1466_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec6"><title>Variant Annotation Assessment (VAA)</title><p id="Par15">Due to the importance of pharmacogenomics on spine pain management, the 125 remaining genes from PPIs, were then checked for their variant annotations. In total, 7019 variant annotations were found, among them, 3088 had a significant annotation according to the <italic toggle="yes">p</italic>-value below 0.05. Furthermore, 47 genes were discarded for having no variant annotations or not significant annotations and 78 candidate genes remained. To be more specific, the genotype associations of variant annotations were then searched for &#8220;pain&#8221; or &#8220;addiction.&#8221; Finally, after omitting the unrelated genotype associations and duplicated annotations, 78 genes and 672 variants remained. Additional deep filtrations based on the functions of variants indicated that there were 302 in total including 222 functional and 80 regulatory variants (29 Promoter, 25 Enhancer, 7 CTCF, 14 Splicing, and 5 overlapped functions variants). The intronic, intergenic, ncRNA, and synonymous variants were discarded. These 302 final filtered variants were related to the 56 genes. Another gene was eliminated as a result of the STRING MODEL described in the following, reducing the number of genes to 55.</p></sec><sec id="Sec7"><title>Signaling Pathway Assessment (SPA)</title><p id="Par16">Cytoscape analysis was carried out to find the signaling pathways which might be helpful for checking the refined gene list (55 genes) and prioritize the genes with higher potential of being drug targets based on the pharmacogenomics approach. Results revealed that 10 genes of out of 55 refined genes were similar with the 34 gene list of Monoamine GPCRs (10 out of 34) as the most related curated pathway with the <italic toggle="yes">p</italic>-value of 3.78e&#8722;13. These 10 genes were: ADRA1A, ADRA2A, ADRB1, CHRM1, DRD2, DRD3, HTR1B, HTR2A, HTR2C, and HTR7 (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). The second most significant pathway was based on the nicotine effect on dopaminergic neurons with a <italic toggle="yes">p</italic>-value of 1.12e&#8722;7.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>The Cytoscape output of 55 genes showing Monoamine GPCRs as the most significant pathway with a <italic toggle="yes">p</italic>-value of 3.78e&#8722;13</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="10571_2024_1466_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec8"><title>Gene&#8211;miRNA Interactions (GMIs)</title><p id="Par17">miRTargetLink2 was applied on the 55 refined genes and adjusted with the strong molecular evidences to reveal the most important genes according to the GMIs. In the center of the concentric model, 13 genes had the maximum shared interactions including <italic toggle="yes">ABCB1, OPRM1, SLC6A4, CYP1B1, GP1BA, PPARA, TRL4, KCNH2, PPARG, PTGS2, BCL2, CFTR</italic>, and <italic toggle="yes">ESR1</italic>. Additionally, one miRNA indicated the maximum shared relationships with the aforementioned genes in the center of the concentric model including hsa-miR-16-5p (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>The concentric model of 55 genes adjusted with strong validated evidences illustrated by miRTargetLink2 representing the most important genes and miRNAs in the candidate opioid gene list</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="10571_2024_1466_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Protein&#8211;Drug Interactions (PDIs)</title><p id="Par18">Analyzing 55 final genes by NetworkAnalyst (according to DrugBank ver. 5) adjusted for senior network, Fruchterman&#8211;Reingold model of PDIs showed important associated drugs. Drugs with the highest degree of betweenness are Ibuprofen and Nicotine with a degree of 4; Tramadol, Dipivefrin, Haloperidol, Ketamine, and Paliperidone with a degree of 3; and <sc>l</sc>-Glutamic Acid, Icosapent, Caffeine, Citalopram, Eletriptan, Atomoxetine, Pentobarbital, Indomethacin, Terfenadine, Naloxone, and Alfuzosin with a degree of 2. The other drugs can be found on Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>The PDIs of 55 genes in a Fruchterman&#8211;Reingold network showing the most potential drugs in association with the PGx of Opioid prescription in Spine pain managements</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="10571_2024_1466_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec10"><title>Protein&#8211;Chemical Interactions (PCIs)</title><p id="Par19">PCIs carried out by NetworkAnalyst based on data from the Comparative Toxicogenomics Database (CTD). Linear Bi/tripartite model adjusted for Steiner Forest Model which indicated at least one chemical for each of 55 target genes. Notably, some target genes had more than 2 interaction including ABCB1 (17 interactions), BCL2 (11 interactions); CYP1A2, KCNH2, and PTGS2 (4 interactions); and some of them had 2 interactions for example DRD2. Thus, ABCB1 was the most important target of suggested chemicals. Additionally, 10 chemicals were found with two interactions with the mentioned target genes including carbamylhydrazine, tetrahydropalmatine, 4-iodo-2, 5-dimethoxyphenylisopropylamine, 2-amino-3, 4-dimethylimidazo(4, 5-f)quinolone, Terazosin, beta-methylcholine, propiconazole, rubimaillin, quinelorane, and 1,3-dipropyl-8-cyclopentylxanthine (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Linear Bi/Tripartite model of PCIs visualized by NetworkAnalyst</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="10571_2024_1466_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec11"><title>Literature Review</title><p id="Par20">According to MeSH (Medical Subject Headings), we searched PubMed using the MeSH guidelines, and selected the titles and subheading of the papers for inclusion criteria (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/help/#using-mesh-database">https://pubmed.ncbi.nlm.nih.gov/help/#using-mesh-database</ext-link>). Reviewing the PubMed database by focusing on the related terms including Pharmacogenomics, opioid, spine, and surgery revealed that there are 42 publications with the keywords of &#8216;Pharmacogenomics&#8217; and &#8216;Opioids&#8217; from 2011 to 2023; 16 papers with the keyword of pharmaocogenomics, opioid, and &#8216;surgery&#8217; from 2008 to 2023 and 3 papers containing pharmacogenomics, opioid, and spine from 2014 to 2023; notably, 2 articles by Cottrill reported similar results. Following exact examination of related publications to this review, 12 papers were relevant and are examined in the discussion section. Figure&#160;<xref rid="Fig6" ref-type="fig">6</xref> summarized a PRISMA workflow containing the details.<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>PRISMA workflow of reviewed studies. *These studies did not include the opioids prescription in surgical operations. **These publications were discarded for Reason 1: opioids in surgery were not their main focus; and Reason 2: they did not about orthopedic surgeries and opioid prescription</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="10571_2024_1466_Fig6_HTML.jpg"/></fig></p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par21">Technology advancements have mitigated many problems related to traditional open spine surgery related to large incisions, extended surgery times and excessive blood loss contributing to postoperative pain. Robotic-guided, navigation-guided, enhanced reality-assisted, minimally invasive and endoscopic spine surgery alternatives have been shown to decrease tissue disruption and operative times (Carrau et al. <xref ref-type="bibr" rid="CR10">2013</xref>; Snyder <xref ref-type="bibr" rid="CR68">2018</xref>; Galetta et al. <xref ref-type="bibr" rid="CR31">2019</xref>), potentially resulting in a shorter length of stay and an accelerated overall recovery (McClelland and Goldstein <xref ref-type="bibr" rid="CR49">2017</xref>).</p><p id="Par22">In addition to these innovative surgical techniques, implementation of enhanced surgical recovery (ERAS) protocols has modernized the way spine surgery patients prepare for, undergo, and recover from surgery (Carr et al. <xref ref-type="bibr" rid="CR9">2019</xref>; Wang et al. <xref ref-type="bibr" rid="CR75">2019</xref>). Sufficient pain control can be obtained through the combination of preoperative education on pain management and improving intraoperative non-opioid pain-management strategies. Employing these pain management strategies in an integrated approach may allow to minimize the use of postoperative opioids significantly.</p><p id="Par23">Moreover, by determining certain patient information, such as (I) preoperative opioid vulnerability according to an individual's genome, (II) surgery type, (III) age, (IV) BMI, (V) depression/anxiety detections, (VI) duration of hospital stay, and (VII) pain scores at hospital discharge, are capable of more accurately predicting opioid consumption patterns. Ideally, prescription methods may be tailored according to the requirements of an individual (Dufour et al. <xref ref-type="bibr" rid="CR24">2014</xref>; Gao et al. <xref ref-type="bibr" rid="CR32">2021</xref>), recognizing that the causes of the opioid crisis are multifaceted, with socioeconomical determinants of health playing an important part (Orosz and Yamout <xref ref-type="bibr" rid="CR57">2023</xref>).</p><p id="Par24">Genetic study on opioid analgesic response has concentrated on selecting SNPs in candidate genes (encoding proteins) which are associated with identified opioid pharmacokinetics and pharmacodynamics and those related to alternate pain-related pathways (L&#246;tsch and Geisslinger <xref ref-type="bibr" rid="CR45">2006</xref>; Kim et al. <xref ref-type="bibr" rid="CR39">2009</xref>). Abundant studies have confirmed differing analgesic responses related to candidate SNPs, remarkably increased postoperative morphine requirements among adults homozygous for &#956; opioid receptor (MOR) variants which is encoded by <italic toggle="yes">OPRM1</italic> A118G, but the findings do not carry across all patient populations (Chou et al. <xref ref-type="bibr" rid="CR14">2006a</xref>, <xref ref-type="bibr" rid="CR15">b</xref>; Chou et al. <xref ref-type="bibr" rid="CR14">2006a</xref>, <xref ref-type="bibr" rid="CR15">b</xref>; Coulbault et al. <xref ref-type="bibr" rid="CR18">2006</xref>; Janicki et al. <xref ref-type="bibr" rid="CR38">2006</xref>). Current candidate gene approaches give clear evidence of the polygenic nature of postoperative pain and opioid analgesic requirement, but continue to limit findings to known pain pathway elements (Coulbault et al. <xref ref-type="bibr" rid="CR18">2006</xref>; Mamie et al. <xref ref-type="bibr" rid="CR46">2013</xref>). A remarkable research by Chen et al. hypothesized that brain reward circuitry genes were genetic antecedents of pain sensitivity and critical diagnostic and also, they focused on pharmacogenomic treatment targets for chronic pain conditions. They introduced the concepts of brain reward cascade (BRC) and reward deficiency syndrome (RDS) both playing vital roles in pain management by opioids. A noticeable number of genes including OPRD1, OPRK1, OPRM1, BDNF, DRD genes (D1&#8211;5), MAO-A, COMT, PDYN, CYP2D6, CYP2B6, CYP2C19, CYP2C9, ABCB1, PENK, CNR1, UGT2B7, TTC12, ANKK1, NCAM1, ZCRB1, GABA(A), the metabotropic receptors mGluR6 and mGluR8, nuclear receptor NR4A2 and cryptochrome 1 (photolyase-like), Dat1, DBH, CAMKII; GnRH; NT-3 genes; G-protein alpha subunits; alpha2-adrenoceptor; interleukin-2; RGS-R7; Gbeta5, serotonin transporter, Ca<sup>2+</sup>/cAMP responsive element binding protein; P-glycoprotein, and CREB (Chen et al. <xref ref-type="bibr" rid="CR11">2009</xref>) have been implied in BRC and RDS.</p><p id="Par25">Here we systematically reviewed 61 publications and found 12 relevant PubMed-indexed publications which are discussed in the following. By studying five tag SNPs including A118G, IVS2&#8201;+&#8201;G691C, IVS3&#8201;+&#8201;G5953A, IVS3&#8201;+&#8201;A8449G, and TAA&#8201;+&#8201;A2109G, Hayashida et al. reported that analgesic necessities following major abdominal surgery are associated with both genotype and haplotype of OPRM1 gene polymorphisms (Hayashida et al. <xref ref-type="bibr" rid="CR35">2008</xref>). Fukuda et al. investigated the association of OPRM1 gene polymorphisms (118G and IVS3&#8201;+&#8201;A8449G) with fentanyl susceptibility among patients experiencing painful cosmetic surgery. Their results offered insight into the role of OPRM1 3&#8242; untranslated region (3&#8242;-UTR) polymorphisms, together with the A118G SNP, in fentanyl sensibility, and opened up new options for individualized pain management with fentanyl (Fukuda et al. <xref ref-type="bibr" rid="CR30">2009</xref>). Cook-Sather et al. conducted the first experimental GWAS in a pediatric day surgery cohort and found no relationships between rs795484 and rs1277441 at the TAOK3 gene with total morphine request in European Caucasian children (Cook-Sather et al. <xref ref-type="bibr" rid="CR16">2014</xref>). We investigated the TAOK3 pharmacogenomics associations in PharmGKB and then included this gene with 55 candidate genes from our analyses, but it showed no molecular connection with any members of candidate genes in a PPIs network by STRING-MODEL. Thus, we excluded TAOK3 from our list. Zhang et al. examined the impact of CYP3A5*3 polymorphism and the association between CYP3A5*3 and CYP3A4*1G variants on fentanyl analgesia following gynecological surgery among Chinese patients. They showed that, in Chinese women having gynecological surgery, CYP3A5*3 was not the primary genetic factor that contributed to inter-individual variation in the post-operative analgesic impact of fentanyl; however, a relationship between CYP3A5*3 and CYP3A4*1G variants can profoundly affect postoperative pain (Zhi-Xue et al. <xref ref-type="bibr" rid="CR82">2023</xref>). The influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia was highlighted in Chinese patients (Zhang et al. <xref ref-type="bibr" rid="CR80">2011</xref>). Senagore et al.'s study was designed to conduct the first evaluation of the effects of a PGx-guided analgesic option in an Enhanced Recovery Protocol (ERP) after major abdominal surgery (Zhao et al. <xref ref-type="bibr" rid="CR81">2022</xref>). They investigated the genes OPRM1, COMT, CYP2C9, CYP2C19,&#160;CYP1A2, CYP2D6, CYP3A4, CYP3A5, and ABCB1. According to their statistics, the groups' gender and procedure mixes were comparable, and over half of the PGx group experienced altered analgesia from the conventional ERP. Post-Op Day 1 (POD 1) (3.8 vs. 5.4) to POD 5 (3.0 vs. 4.5) showed substantially lower Overall Benefit of Analgesia Score (OBAS) ratings (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0.1) for the PGx group. In POD 1 to POD 5, the PGx group's analgesia was additionally better (<italic toggle="yes">p</italic>&#8201;=&#8201;0.04). They came to the conclusion that 80% of patients had narcotic alterations of the ERP analgesic scheme and 56% of patients had NSAID selection based on pharmacogenetic advice utilizing the multi-gene profile analyzed. Compared to their normal ERP, these adjustments produced good analgesia with a 50% decrease in narcotic intake and a reduced risk of analgesic-related adverse reactions. These findings pointed to potential areas of improvement for ERP deriving from a patient-centered, lower-narcotic analgesic regimen that offers early and long-lasting pain relief with fewer adverse effects associated with opioid use (Senagore et al. <xref ref-type="bibr" rid="CR66">2017</xref>). Rocco et al. hypothesized that pharmacogenomic detection of individuals with varying opioid metabolism capability might allow for individualization of post-surgical opioid prescriptions. This study proposed an association between genetically regulated metabolism and opioid needs following surgery. Enhanced CYP2D6 enzymatic activity was linked to higher opioid intake, fewer unused opioids, and worse satisfaction with opioid prescriptions (Rocco et al. <xref ref-type="bibr" rid="CR61">2019</xref>). Li et al. identified 27 SNPs from 9 genes, including ABCB1, COMT, ARRB2, DRD2, MC1R, KCNJ6, OPRM1, OPRD1, and UGT2B7, that matched selection criteria and were evaluated with TAOK3. Morphine dose in African American (AA) children and ABCB1 rs1045642 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.02) and OPRM1 rs1799971 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.02); KCNJ6 rs2211843 and high pain in AA subjects (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01) and in congruent European Caucasian pain phenotypes (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01); and COMT rs740603 for high pain in European Caucasian individuals (<italic toggle="yes">p</italic>&#8201;=&#8201;0.046). According to Li et al., TAOK3 (rs795484) is still a major contributor to high morphine dosage requirements in European Caucasian people (Li et al. <xref ref-type="bibr" rid="CR42">2019a</xref>, <xref ref-type="bibr" rid="CR43">b</xref>).</p><p id="Par26">Along these lines, Ettienne et al. (<xref ref-type="bibr" rid="CR27">2019</xref>) importantly, conducted a retrospective cohort study of 113 patients undergoing buprenorphine-based OUD management in Northeast Washington, DC to find if clinical pharmacogenomics testing for CYP3A4 and CYP3A5 would influence treatment consequences. Clinical outcomes were based on presence of withdrawal symptoms, instances of unauthorized substances in urine drug tests (UDTs), and sublingual buprenorphine/naloxone (SBN) dose with standard-of-care (SOC) dosing versus pharmacogenomics (PGx)-based dosing. Their research suggested that patients with at least one copy of the CYP3A4*1B allele exhibit an accelerated rate of metabolism compared to the wild-type allele CYP3A4*1. These findings have translated in novel approaches in the treatment of pain and addiction by the same group (Ettienne et al. <xref ref-type="bibr" rid="CR26">2017</xref>). They suggested that pharmacogenomic testing as clinical decision support helped to individualize OUD management. They further suggested that collaboration by key stakeholders is essential to establishing pharmacogenetic testing as standard of care in OUD management.</p><p id="Par27">Matic et al. examined the possible function of OPRM1 and COMT variants in acute, chronic, and experimental thermal pain following adult heart surgery. The subjects were randomly assigned to receive remifentanil or fentanyl throughout the procedure. They discovered that in adult cardiac surgery individuals, the COMT haplotype can partially account for the variation in early postoperative pain (Matic et al. <xref ref-type="bibr" rid="CR48">2020</xref>). Merchant et al. demonstrated that the association of CYP2D6 genotype can predict phenotypes with higher oxycodone requirements and adverse effects among children who underwent surgery. They genotyped <italic toggle="yes">CYP2D6</italic> alleles by the TaqMan allelic discrimination system in three allelic groups including full enzyme activity [*1 (N/A), *2 (rs16947), *2A (hCV32407252), *35 (rs769258)]; reduced enzyme activity [*9 (rs5030656), *10 (rs1065852), *17 (hCV2222771), *41 (hCV34816116)]; and none enzyme activity [<italic toggle="yes">*3</italic> (hCV32407232), <italic toggle="yes">*4</italic> (rs3892097), <italic toggle="yes">*5</italic> (deleted), <italic toggle="yes">*6</italic> (rs5030655), <italic toggle="yes">*7</italic> (rs5030867), <italic toggle="yes">*8</italic> (rs5030865), <italic toggle="yes">*11</italic> (rs5030863), <italic toggle="yes">*14</italic> (rs5030865), <italic toggle="yes">*15</italic> (hCV32407245), <italic toggle="yes">*18</italic> (hCV32407220), <italic toggle="yes">*19</italic> (hCV32407233), <italic toggle="yes">*20</italic> (hCV72649949), <italic toggle="yes">*40</italic> (hCV32407240), <italic toggle="yes">*42</italic> (hCV72649935), <italic toggle="yes">*44</italic> (hCV32407228)]. Their results revealed that increasing parent oxycodone and oxymorphone might affect clinical outcomes in severe phenotypes, but oxymorphone might have a superior safety profile. They also discovered that CYP2D6 phenotype data accessible in electronic medical records (EMR) strongly affected oral opioid prescribing patterns (Merchant et al. <xref ref-type="bibr" rid="CR53">2022</xref>). Prashant and colleagues studied the association of pain perception and fentanyl consumption following major abdominal surgery with CGRP 4218T/C variant. They discovered that this variation influences postoperative pain perception and analgesic intake. Patients who carried the C/C genotype had greater postoperative fentanyl intake and pain ratings, according to the researchers (Prashant et al. <xref ref-type="bibr" rid="CR60">2023</xref>).</p><p id="Par28">To the best of our knowledge based on PubMed database, publications related to the pharmacogenomics in spine pain managements are limited to two reports including Chidambaran et al. (<xref ref-type="bibr" rid="CR13">2015</xref>) and Cottrill et al. (<xref ref-type="bibr" rid="CR17">2021</xref>) Chidambaran et al. performed a prospective genotype-blinded research on 88 healthy adolescents (aged 11&#8211;18&#160;years; 85% Caucasian, 67% female) who had spine fusion surgery for scoliosis. They were observed for 48&#160;h following surgery to assess pain levels, analgesic adjuvant usage, morphine intake, and morphine-induced respiratory depression (MIRD). OPRM1 A118G variant genotyping revealed that 76% of patients were wild type (AA) and 24% were heterozygous/homozygous for the variation (AG/GG). Results showed that the risk of MIRD in patients with AA genotype was significantly higher (<italic toggle="yes">p</italic>&#8201;=&#8201;0.030) and presence of G allele was also associated with higher pain scores (<italic toggle="yes">p</italic>&#8201;=&#8201;0.045) (Chidambaran et al. <xref ref-type="bibr" rid="CR13">2015</xref>). Cottrill et al. studied genotypes of genes including <italic toggle="yes">CYP2D6, CYP1A2, CYP2C9, CYP3A4, CYP3A5, CYP2B6, CYP2C19</italic>, and <italic toggle="yes">UGT2B7</italic>. Haplotypes were then utilized to assess each patient&#8217;s relative capability to metabolize commonly used analgesic drugs. These drugs included both non-opioid (for example ibuprofen, diclofenac, mefenamic acid, nabumetone, indomethacin, piroxicam, meloxicam, tenoxicam, lornoxicam, etoricoxib, parecoxib, celecoxib, flurbiprofen, ketoprofen, fenoprofen, hydrocodone, naproxen, and aspirin) and opioid analgesics (including morphine, ethylmorphine, hydromorphone, codeine, dihydrocodeine, methadone, hydrocodone, oxycodone, oxymorphone, alfentanil, fentanyl, sufentanil, meperidine, ketobemidone, dextropropoxyphene, levacetylmethadol, loperamide, buprenorphine, dextromethorphan, tramadol, tapentadol, and tilidine). They constructed the first pharmacogenetic profiles of an outpatient spine cohort and gave preliminary proof that an outpatient analgesic regimen consisting of one medication since they are poor metabolizers. They discovered that almost half of the patients were given one analgesic because they had genetic variants that caused them to be poor metabolizers of the medication. Given the existing opioid epidemic, 13 of the 19 patients (68%) who were taking opioid drugs at the time of examination were excessively fast metabolizers of their prescription opioid analgesic (Cottrill et al. <xref ref-type="bibr" rid="CR17">2021</xref>). The current review is the first report with a pharmacogenomics-based strategy of analyzing all FDA-approved drugs (as of 9 November 2023) by targeting protein-coding genes and filtering the structural and regulatory pharmacological actionable variants. Our report, in comparison with the most relevant reports by Chidambaran et al. (<xref ref-type="bibr" rid="CR13">2015</xref>). and Cottrill et al. (<xref ref-type="bibr" rid="CR17">2021</xref>), included more genes (128 genes were filtered down to 55 genes), and a comprehensive variant list, and multiple in silico analyses including PPIs, GMIs, PDIs, and PCIs leading to several crucial findings which are highly recommended to be investigated in future studies of opioid prescribing in spine pain managements.</p><p id="Par29">Based on the strong molecular evidences, in silico outcomes represented 55 candidate genes and 302 potential actionable variants. Additionally, results of signaling pathways proposed the Monoamine GPCRs as the most significant signaling pathway of opioid prescribing in spine pain managements, GMIs suggested hsa-miR-16-5p as a prospective miRNA candidate for detection and prognosis, PDIs revealed Ibuprofen and Nicotine, Tramadol, Dipivefrin, Haloperidol, Ketamine, and Paliperidone as the highly-impacted drugs on opioid prescription, and PCI analysis indicated some target genes with more than two interaction including <italic toggle="yes">ABCB1, BCL2, CYP1A2, KCNH2, PTGS2</italic>, and <italic toggle="yes">DRD2</italic>. Also, 10 chemicals were found by PCIs which need more functional validations.</p><p id="Par30">Hou et al. revealed that miR-16 plays a key role in the post-transcriptional regulation of the OPRM1 gene. They stated that morphine decreases the expression of miR-16-5p in lymphocytes, which may be reversed by the antagonist naloxone (Hou et al. <xref ref-type="bibr" rid="CR36">2016a</xref>, <xref ref-type="bibr" rid="CR37">b</xref>). Remarkably, miR-16-5p inhibits MOR expression by binding to a position in its 3&#8242; UTR that is situated within 8699 and 8719 nucleotides from the stop codon (Hou et al. <xref ref-type="bibr" rid="CR36">2016a</xref>, <xref ref-type="bibr" rid="CR37">b</xref>). According to Melo et al., miR-16-5p downregulation serves as a post-transcriptional process via which morphine increases MOR receptor concentrations through stabilizing its mRNA. (Melo et al. <xref ref-type="bibr" rid="CR52">2018</xref>). In another report by Chen et al., they suggested that by targeting RAB23 and inhibiting p38 MAPK activation in rats, miR-16 relieves chronic inflammatory pain (Chen et al. <xref ref-type="bibr" rid="CR12">2016</xref>). Following subcutaneous capsaicin injection, Kusuda et al. discovered that miR-16 expression was raised in the dorsal root ganglion (DRG) but reduced in the dorsal spinal cord (Kusuda et al. <xref ref-type="bibr" rid="CR41">2011</xref>). Furthermore, miR-16 was predicted to target BDNF. The <italic toggle="yes">BDNF</italic> gene was additionally a direct target of the miR-183 and miR-206, both of which were found to be downregulated in neuropathic pain (Lin et al. <xref ref-type="bibr" rid="CR44">2014</xref>; Sun et al. <xref ref-type="bibr" rid="CR69">2017</xref>) Additionally, their down-regulation was correlated with an increase in the expression of BDNF. In the spinal cord Chronic Compression Injury (CCI) model, it was also demonstrated that miR-183 was downregulated in neurons and microglial cells (Xie et al. <xref ref-type="bibr" rid="CR79">2017</xref>). Consequently, in microglia, miRNAs were connected to the BDNF signaling pathway (Dai et al. <xref ref-type="bibr" rid="CR20">2018</xref>). According to Li et al., in the spinal cord of CCI rats, interleukin-1&#946; and tumor-necrosis factor-&#945; expression were downregulated with suppression of miR-15a and miR-16. Using bioinformatics, they discovered that a potential target gene for miR-15a and miR-16 is G protein-coupled receptor kinase 2 (GRK2), is a crucial regulator of neuropathic pain and inflammation. According to their final results, the GRK2 gene is targeted by miR-15a/16 expression suppression, which reduces the development of neuropathic pain (Li et al. <xref ref-type="bibr" rid="CR42">2019a</xref>, <xref ref-type="bibr" rid="CR43">b</xref>). Finally, Toyama et al. showed that miR-16-5p is a circulating blood biomarker which is commonly downregulated by both hydromorphone and oxycodone treatment with a <italic toggle="yes">p</italic>-value of 0.003 (Toyama et al. <xref ref-type="bibr" rid="CR72">2017</xref>). Altogether, miR-16-5p can be further studied for a candidate biomarker in post-operative opioid prescribing in spine pain management along with the genotyping of potential variants based on each individual&#8217;s genomic vulnerabilities.</p></sec><sec id="Sec13"><title>Summary</title><p id="Par31">Variants in patients might affect both pharmacokinetic and pharmacodynamic characteristics of the drugs, which define drug metabolism and effectiveness. (Scott et al. <xref ref-type="bibr" rid="CR65">2019</xref>). Several drugs, for example opioids have these two factors involved due to drug modifications via the cytochrome P450 (CYP450) system in the liver changing the biological activity of the substance. Prior study has indicated that such variants are rare (Smith <xref ref-type="bibr" rid="CR67">2009</xref>), but their incidence in individuals with spine disorders is unclear. Knowing the incidence of these variants may assist patients in achieving better results since identifying inappropriate pharmaceutical analgesic regimens during clinical assessment may help maximize nonoperative treatment. This advancement, in turn, might reduce healthcare expenses while improving patient satisfaction by saving certain patients from the risks related to surgical intervention (Downs et al. <xref ref-type="bibr" rid="CR23">2019</xref>; Cottrill et al. <xref ref-type="bibr" rid="CR17">2021</xref>).</p></sec><sec id="Sec14"><title>Conclusion</title><p id="Par32">The current review aimed to investigate the impact of pharmacogenomics in opioid prescribing of postoperative patients who underwent spine surgery to manage the pain severity and reduce the use of opioids. This goal leads to the personalized medicine strategies of opioid use according to the individual&#8217;s genotypes dictated to the potential candidate variants. The outcomes of this study indicated 56 highly-impacted genes. Additional in silico analyses showed novel findings in PPIs, GMIs, PDIs, and PCIs which need further functional and clinical validations.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are thankful of all database developers and bioinformaticians enhancing big data analysis.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>AS and KUL wrote the main manuscript text and prepared figures. All authors reviewed and edited the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by NIH HHS/United States (Grant No. R41 MD012318/MD/NIMHD).</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>The data that support the findings of this study are available on request from the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par34">Dr. Kenneth Blum is the holder of many patents in the USA and abroad related to GARS and KB220. He has licensed his invention non-exclusively to Victory Nutrition International (VNI).</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Aaron D (2023) The fall of FDA review. Yale J Health Policy Law Ethics 95</mixed-citation></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>A</given-names></name><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Bowirrat</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>Fugel</surname><given-names>D</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>A</given-names></name><name name-style="western"><surname>Fitch</surname><given-names>T</given-names></name><name name-style="western"><surname>Downs</surname><given-names>BW</given-names></name><name name-style="western"><surname>Bagchi</surname><given-names>D</given-names></name></person-group><article-title>DNA directed pro-dopamine regulation coupling subluxation repair, H-Wave&#174; and other neurobiologically based modalities to address complexities of chronic pain in a female diagnosed with reward deficiency syndrome (RDS): emergence of Induction of &#8220;Dopamine Homeostasis&#8221; in the face of the opioid crisis</article-title><source>J Pers Med</source><year>2022</year><volume>12</volume><issue>9</issue><fpage>1416</fpage><pub-id pub-id-type="doi">10.3390/jpm12091416</pub-id><pub-id pub-id-type="pmid">36143203</pub-id><pub-id pub-id-type="pmcid">PMC9503998</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bajaj A, Blum K, Bowirrat A, Gupta A, Baron D, Fugel D, Nicholson A, Fitch T, Downs BW, Bagchi D (2022) DNA directed pro-dopamine regulation coupling subluxation repair, H-Wave&#174; and other neurobiologically based modalities to address complexities of chronic pain in a female diagnosed with reward deficiency syndrome (RDS): emergence of Induction of &#8220;Dopamine Homeostasis&#8221; in the face of the opioid crisis. J Pers Med 12(9):1416. 10.3390/jpm12091416<pub-id pub-id-type="pmid">36143203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm12091416</pub-id><pub-id pub-id-type="pmcid">PMC9503998</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Lott</surname><given-names>L</given-names></name><name name-style="western"><surname>Siwicki</surname><given-names>D</given-names></name><name name-style="western"><surname>Fried</surname><given-names>L</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>M</given-names></name><name name-style="western"><surname>Simpatico</surname><given-names>T</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>Howeedy</surname><given-names>A</given-names></name><name name-style="western"><surname>Badgaiyan</surname><given-names>RD</given-names></name></person-group><article-title>Genetic addiction risk score (GARS&#8482;) as a predictor of substance use disorder: identifying predisposition not diagnosis</article-title><source>Curr Trends Med Diagn Methods</source><year>2018</year><pub-id pub-id-type="doi">10.29011/CTMDM-101.100001</pub-id><pub-id pub-id-type="pmid">31276118</pub-id><pub-id pub-id-type="pmcid">PMC6604806</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Blum K, Lott L, Siwicki D, Fried L, Hauser M, Simpatico T, Baron D, Howeedy A, Badgaiyan RD (2018) Genetic addiction risk score (GARS&#8482;) as a predictor of substance use disorder: identifying predisposition not diagnosis. Curr Trends Med Diagn Methods. 10.29011/CTMDM-101.100001<pub-id pub-id-type="pmid">31276118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.29011/CTMDM-101.100001</pub-id><pub-id pub-id-type="pmcid">PMC6604806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Bowirrat</surname><given-names>A</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>Lott</surname><given-names>L</given-names></name><name name-style="western"><surname>Ponce</surname><given-names>J</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>R</given-names></name><name name-style="western"><surname>Siwicki</surname><given-names>D</given-names></name><name name-style="western"><surname>Boyett</surname><given-names>B</given-names></name><name name-style="western"><surname>Gondre-Lewis</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D</given-names></name></person-group><article-title>Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)</article-title><source>J Syst Integr Neurosci</source><year>2020</year><pub-id pub-id-type="doi">10.15761/JSIN.1000221</pub-id><pub-id pub-id-type="pmid">33614164</pub-id><pub-id pub-id-type="pmcid">PMC7891477</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Blum K, Bowirrat A, Baron D, Lott L, Ponce J, Brewer R, Siwicki D, Boyett B, Gondre-Lewis M, Smith D (2020) Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD). J Syst Integr Neurosci. 10.15761/JSIN.1000221<pub-id pub-id-type="pmid">33614164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15761/JSIN.1000221</pub-id><pub-id pub-id-type="pmcid">PMC7891477</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Bowirrat</surname><given-names>A</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>MCG</given-names></name><name name-style="western"><surname>Simpatico</surname><given-names>TA</given-names></name><name name-style="western"><surname>Ceccanti</surname><given-names>M</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Modestino</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Thanos</surname><given-names>PK</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>T</given-names></name></person-group><article-title>Exploration of epigenetic state hyperdopaminergia (Surfeit) and genetic trait hypodopaminergia (Deficit) during adolescent brain development</article-title><source>Curr Psychopharmacol</source><year>2021</year><pub-id pub-id-type="doi">10.2174/2211556010666210215155509</pub-id><pub-id pub-id-type="pmid">34707969</pub-id><pub-id pub-id-type="pmcid">PMC8547282</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Blum K, Bowirrat A, Lewis MCG, Simpatico TA, Ceccanti M, Steinberg B, Modestino EJ, Thanos PK, Baron D, McLaughlin T (2021) Exploration of epigenetic state hyperdopaminergia (Surfeit) and genetic trait hypodopaminergia (Deficit) during adolescent brain development. Curr Psychopharmacol. 10.2174/2211556010666210215155509<pub-id pub-id-type="pmid">34707969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/2211556010666210215155509</pub-id><pub-id pub-id-type="pmcid">PMC8547282</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Brodie</surname><given-names>MS</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>SC</given-names></name><name name-style="western"><surname>Cadet</surname><given-names>JL</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Elman</surname><given-names>I</given-names></name><name name-style="western"><surname>Thanos</surname><given-names>PK</given-names></name><name name-style="western"><surname>Gondre-Lewis</surname><given-names>MC</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>S</given-names></name></person-group><article-title>Researching mitigation of alcohol binge drinking in polydrug abuse: KCNK13 and RASGRF2 gene(s) risk polymorphisms coupled with genetic addiction risk severity (GARS) guiding precision pro-dopamine regulation</article-title><source>J Pers Med</source><year>2022</year><volume>12</volume><issue>6</issue><fpage>1009</fpage><pub-id pub-id-type="doi">10.3390/jpm12061009</pub-id><pub-id pub-id-type="pmid">35743793</pub-id><pub-id pub-id-type="pmcid">PMC9224860</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Blum K, Brodie MS, Pandey SC, Cadet JL, Gupta A, Elman I, Thanos PK, Gondre-Lewis MC, Baron D, Kazmi S (2022a) Researching mitigation of alcohol binge drinking in polydrug abuse: KCNK13 and RASGRF2 gene(s) risk polymorphisms coupled with genetic addiction risk severity (GARS) guiding precision pro-dopamine regulation. J Pers Med 12(6):1009. 10.3390/jpm12061009<pub-id pub-id-type="pmid">35743793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm12061009</pub-id><pub-id pub-id-type="pmcid">PMC9224860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Han</surname><given-names>D</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>Braverman</surname><given-names>ER</given-names></name><name name-style="western"><surname>Dennen</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>S</given-names></name><name name-style="western"><surname>Llanos-Gomez</surname><given-names>L</given-names></name><name name-style="western"><surname>Badgaiyan</surname><given-names>RD</given-names></name><name name-style="western"><surname>Elman</surname><given-names>I</given-names></name></person-group><article-title>Statistical validation of risk alleles in genetic addiction risk severity (GARS) test: early identification of risk for alcohol use disorder (AUD) in 74,566 case&#8211;control subjects</article-title><source>J Pers Med</source><year>2022</year><volume>12</volume><issue>9</issue><fpage>1385</fpage><pub-id pub-id-type="doi">10.3390/jpm12091385</pub-id><pub-id pub-id-type="pmid">36143170</pub-id><pub-id pub-id-type="pmcid">PMC9505592</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Blum K, Han D, Gupta A, Baron D, Braverman ER, Dennen CA, Kazmi S, Llanos-Gomez L, Badgaiyan RD, Elman I (2022b) Statistical validation of risk alleles in genetic addiction risk severity (GARS) test: early identification of risk for alcohol use disorder (AUD) in 74,566 case&#8211;control subjects. J Pers Med 12(9):1385. 10.3390/jpm12091385<pub-id pub-id-type="pmid">36143170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm12091385</pub-id><pub-id pub-id-type="pmcid">PMC9505592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><mixed-citation publication-type="other">B&#246;ttcher L, Chou T, D'Orsogna MR (2023) Forecasting drug overdose mortality by age in the United States at the national and county levels. medRxiv. 10.1101/2023.09.25.23296097<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pnasnexus/pgae050</pub-id><pub-id pub-id-type="pmcid">PMC11079616</pub-id><pub-id pub-id-type="pmid">38725534</pub-id></mixed-citation></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carr</surname><given-names>DA</given-names></name><name name-style="western"><surname>Saigal</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Bransford</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Bellabarba</surname><given-names>C</given-names></name><name name-style="western"><surname>Dagal</surname><given-names>A</given-names></name></person-group><article-title>Enhanced perioperative care and decreased cost and length of stay after elective major spinal surgery</article-title><source>Neurosurg Focus</source><year>2019</year><volume>46</volume><issue>4</issue><fpage>E5</fpage><pub-id pub-id-type="doi">10.3171/2019.1.FOCUS18630</pub-id><pub-id pub-id-type="pmid">30933922</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Carr DA, Saigal R, Zhang F, Bransford RJ, Bellabarba C, Dagal A (2019) Enhanced perioperative care and decreased cost and length of stay after elective major spinal surgery. Neurosurg Focus 46(4):E5. 10.3171/2019.1.FOCUS18630<pub-id pub-id-type="pmid">30933922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2019.1.FOCUS18630</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrau</surname><given-names>RL</given-names></name><name name-style="western"><surname>Prevedello</surname><given-names>DM</given-names></name><name name-style="western"><surname>de Lara</surname><given-names>D</given-names></name><name name-style="western"><surname>Durmus</surname><given-names>K</given-names></name><name name-style="western"><surname>Ozer</surname><given-names>E</given-names></name></person-group><article-title>Combined transoral robotic surgery and endoscopic endonasal approach for the resection of extensive malignancies of the skull base</article-title><source>Head Neck</source><year>2013</year><volume>35</volume><issue>11</issue><fpage>E351</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1002/hed.23238</pub-id><pub-id pub-id-type="pmid">23468360</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Carrau RL, Prevedello DM, de Lara D, Durmus K, Ozer E (2013) Combined transoral robotic surgery and endoscopic endonasal approach for the resection of extensive malignancies of the skull base. Head Neck 35(11):E351-358. 10.1002/hed.23238<pub-id pub-id-type="pmid">23468360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.23238</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>AL-C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Waite</surname><given-names>RL</given-names></name><name name-style="western"><surname>Reinking</surname><given-names>J</given-names></name><name name-style="western"><surname>Tung</surname><given-names>HL</given-names></name><name name-style="western"><surname>Rhoades</surname><given-names>P</given-names></name><name name-style="western"><surname>Downs</surname><given-names>BW</given-names></name><name name-style="western"><surname>Braverman</surname><given-names>E</given-names></name><name name-style="western"><surname>Braverman</surname><given-names>D</given-names></name><name name-style="western"><surname>Kerner</surname><given-names>M</given-names></name></person-group><article-title>Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions</article-title><source>Med Hypotheses</source><year>2009</year><volume>72</volume><issue>1</issue><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2008.07.059</pub-id><pub-id pub-id-type="pmid">18951726</pub-id><pub-id pub-id-type="pmcid">PMC4098664</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chen AL-C, Chen TJ, Waite RL, Reinking J, Tung HL, Rhoades P, Downs BW, Braverman E, Braverman D, Kerner M (2009) Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Med Hypotheses 72(1):14&#8211;22. 10.1016/j.mehy.2008.07.059<pub-id pub-id-type="pmid">18951726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mehy.2008.07.059</pub-id><pub-id pub-id-type="pmcid">PMC4098664</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>MicroRNA-16 alleviates inflammatory pain by targeting Ras-related protein 23 (RAB23) and inhibiting p38 MAPK activation</article-title><source>Med Sci Monit Int Med J Exp Clin Res</source><year>2016</year><volume>22</volume><fpage>3894</fpage><pub-id pub-id-type="doi">10.12659/msm.897580</pub-id><pub-id pub-id-type="pmcid">PMC5081236</pub-id><pub-id pub-id-type="pmid">27770129</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Chen W, Guo S, Wang S (2016) MicroRNA-16 alleviates inflammatory pain by targeting Ras-related protein 23 (RAB23) and inhibiting p38 MAPK activation. Med Sci Monit Int Med J Exp Clin Res 22:3894. 10.12659/msm.897580<pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.897580</pub-id><pub-id pub-id-type="pmcid">PMC5081236</pub-id><pub-id pub-id-type="pmid">27770129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chidambaran</surname><given-names>V</given-names></name><name name-style="western"><surname>Mavi</surname><given-names>J</given-names></name><name name-style="western"><surname>Esslinger</surname><given-names>H</given-names></name><name name-style="western"><surname>Pilipenko</surname><given-names>V</given-names></name><name name-style="western"><surname>Martin</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Sadhasivam</surname><given-names>S</given-names></name></person-group><article-title>Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents</article-title><source>Pharmacogenomics J</source><year>2015</year><volume>15</volume><issue>3</issue><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/tpj.2014.59</pub-id><pub-id pub-id-type="pmid">25266679</pub-id><pub-id pub-id-type="pmcid">PMC4406866</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Chidambaran V, Mavi J, Esslinger H, Pilipenko V, Martin L, Zhang K, Sadhasivam S (2015) Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents. Pharmacogenomics J 15(3):255&#8211;262. 10.1038/tpj.2014.59<pub-id pub-id-type="pmid">25266679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tpj.2014.59</pub-id><pub-id pub-id-type="pmcid">PMC4406866</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>W-Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C-H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P-H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Jawan</surname><given-names>B</given-names></name></person-group><article-title>Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy</article-title><source>J Am Soc Anesthesiol</source><year>2006</year><volume>105</volume><issue>2</issue><fpage>334</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1097/00000542-200608000-00016</pub-id><pub-id pub-id-type="pmid">16871067</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Chou W-Y, Wang C-H, Liu P-H, Liu C-C, Tseng C-C, Jawan B (2006a) Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. J Am Soc Anesthesiol 105(2):334&#8211;337. 10.1097/00000542-200608000-00016<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200608000-00016</pub-id><pub-id pub-id-type="pmid">16871067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>WY</given-names></name><name name-style="western"><surname>Yang</surname><given-names>LC</given-names></name><name name-style="western"><surname>Lu</surname><given-names>HF</given-names></name><name name-style="western"><surname>Ko</surname><given-names>JY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>TH</given-names></name><name name-style="western"><surname>Concejero</surname><given-names>A</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CJ</given-names></name></person-group><article-title>Association of &#956;-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty</article-title><source>Acta Anaesthesiol Scand</source><year>2006</year><volume>50</volume><issue>7</issue><fpage>787</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.2006.01058.x</pub-id><pub-id pub-id-type="pmid">16879459</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ (2006b) Association of &#956;-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50(7):787&#8211;792. 10.1111/j.1399-6576.2006.01058.x<pub-id pub-id-type="pmid">16879459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1399-6576.2006.01058.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cook-Sather</surname><given-names>SD</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Goebel</surname><given-names>TK</given-names></name><name name-style="western"><surname>Sussman</surname><given-names>EM</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hakonarson</surname><given-names>H</given-names></name></person-group><article-title>TAOK3, a novel genome-wide association study locus associated with morphine requirement and postoperative pain in a retrospective pediatric day surgery population</article-title><source>PAIN&#174;</source><year>2014</year><volume>155</volume><issue>9</issue><fpage>1773</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2014.05.032</pub-id><pub-id pub-id-type="pmid">24909733</pub-id><pub-id pub-id-type="pmcid">PMC4157963</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Cook-Sather SD, Li J, Goebel TK, Sussman EM, Rehman MA, Hakonarson H (2014) TAOK3, a novel genome-wide association study locus associated with morphine requirement and postoperative pain in a retrospective pediatric day surgery population. PAIN&#174; 155(9):1773&#8211;1783. 10.1016/j.pain.2014.05.032<pub-id pub-id-type="pmid">24909733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2014.05.032</pub-id><pub-id pub-id-type="pmcid">PMC4157963</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cottrill</surname><given-names>E</given-names></name><name name-style="western"><surname>Pennington</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>AK</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name><name name-style="western"><surname>Ehresman</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>A</given-names></name><name name-style="western"><surname>Perdomo-Pantoja</surname><given-names>A</given-names></name><name name-style="western"><surname>Lubelski</surname><given-names>D</given-names></name><name name-style="western"><surname>Sciubba</surname><given-names>DM</given-names></name><name name-style="western"><surname>Witham</surname><given-names>T</given-names></name></person-group><article-title>First report of pharmacogenomic profiling in an outpatient spine setting: preliminary results from a pilot study</article-title><source>World Neurosurg</source><year>2021</year><volume>145</volume><fpage>e21</fpage><lpage>e31</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2020.09.007</pub-id><pub-id pub-id-type="pmid">32916348</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Cottrill E, Pennington Z, Ahmed AK, Jiang B, Ehresman J, Zhu A, Perdomo-Pantoja A, Lubelski D, Sciubba DM, Witham T (2021) First report of pharmacogenomic profiling in an outpatient spine setting: preliminary results from a pilot study. World Neurosurg 145:e21&#8211;e31. 10.1016/j.wneu.2020.09.007<pub-id pub-id-type="pmid">32916348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2020.09.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coulbault</surname><given-names>L</given-names></name><name name-style="western"><surname>Beaussier</surname><given-names>M</given-names></name><name name-style="western"><surname>Verstuyft</surname><given-names>C</given-names></name><name name-style="western"><surname>Weickmans</surname><given-names>H</given-names></name><name name-style="western"><surname>Dubert</surname><given-names>L</given-names></name><name name-style="western"><surname>Tr&#233;gouet</surname><given-names>D</given-names></name><name name-style="western"><surname>Descot</surname><given-names>C</given-names></name><name name-style="western"><surname>Parc</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lienhart</surname><given-names>A</given-names></name><name name-style="western"><surname>Jaillon</surname><given-names>P</given-names></name></person-group><article-title>Environmental and genetic factors associated with morphine response in the postoperative period</article-title><source>Clin Pharmacol Ther</source><year>2006</year><volume>79</volume><issue>4</issue><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2006.01.007</pub-id><pub-id pub-id-type="pmid">16580900</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Tr&#233;gouet D, Descot C, Parc Y, Lienhart A, Jaillon P (2006) Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 79(4):316&#8211;324. 10.1016/j.clpt.2006.01.007<pub-id pub-id-type="pmid">16580900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2006.01.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cram</surname><given-names>P</given-names></name><name name-style="western"><surname>Landon</surname><given-names>BE</given-names></name><name name-style="western"><surname>Matelski</surname><given-names>J</given-names></name><name name-style="western"><surname>Ling</surname><given-names>V</given-names></name><name name-style="western"><surname>Perruccio</surname><given-names>AV</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rampersaud</surname><given-names>YR</given-names></name></person-group><article-title>Utilization and outcomes for spine surgery in the United States and Canada</article-title><source>Spine (phila Pa 1976)</source><year>2019</year><volume>44</volume><issue>19</issue><fpage>1371</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1097/BRS.0000000000003083</pub-id><pub-id pub-id-type="pmid">31261267</pub-id><pub-id pub-id-type="pmcid">PMC6746582</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Cram P, Landon BE, Matelski J, Ling V, Perruccio AV, Paterson JM, Rampersaud YR (2019) Utilization and outcomes for spine surgery in the United States and Canada. Spine (phila Pa 1976) 44(19):1371&#8211;1380. 10.1097/BRS.0000000000003083<pub-id pub-id-type="pmid">31261267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0000000000003083</pub-id><pub-id pub-id-type="pmcid">PMC6746582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name></person-group><article-title>The regulatory mechanisms and therapeutic potential of microRNAs: from chronic pain to morphine tolerance</article-title><source>Front Mol Neurosci</source><year>2018</year><volume>11</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2018.00080</pub-id><pub-id pub-id-type="pmid">29615865</pub-id><pub-id pub-id-type="pmcid">PMC5864932</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Dai Z, Chu H, Ma J, Yan Y, Zhang X, Liang Y (2018) The regulatory mechanisms and therapeutic potential of microRNAs: from chronic pain to morphine tolerance. Front Mol Neurosci 11:80. 10.3389/fnmol.2018.00080<pub-id pub-id-type="pmid">29615865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2018.00080</pub-id><pub-id pub-id-type="pmcid">PMC5864932</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasgupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Beletsky</surname><given-names>L</given-names></name><name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></name></person-group><article-title>Opioid crisis: no easy fix to its social and economic determinants</article-title><source>Am J Public Health</source><year>2018</year><volume>108</volume><issue>2</issue><fpage>182</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2017.304187</pub-id><pub-id pub-id-type="pmid">29267060</pub-id><pub-id pub-id-type="pmcid">PMC5846593</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Dasgupta N, Beletsky L, Ciccarone D (2018) Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health 108(2):182&#8211;186. 10.2105/AJPH.2017.304187<pub-id pub-id-type="pmid">29267060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/AJPH.2017.304187</pub-id><pub-id pub-id-type="pmcid">PMC5846593</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dennen</surname><given-names>CA</given-names></name><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Bowirrat</surname><given-names>A</given-names></name><name name-style="western"><surname>Thanos</surname><given-names>PK</given-names></name><name name-style="western"><surname>Elman</surname><given-names>I</given-names></name><name name-style="western"><surname>Ceccanti</surname><given-names>M</given-names></name><name name-style="western"><surname>Badgaiyan</surname><given-names>RD</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>T</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>A</given-names></name></person-group><article-title>Genetic addiction risk severity assessment identifies polymorphic reward genes as antecedents to reward deficiency syndrome (RDS) hypodopaminergia&#8217;s effect on addictive and non-addictive behaviors in a nuclear family</article-title><source>J Pers Med</source><year>2022</year><volume>12</volume><issue>11</issue><fpage>1864</fpage><pub-id pub-id-type="doi">10.3390/jpm12111864</pub-id><pub-id pub-id-type="pmid">36579592</pub-id><pub-id pub-id-type="pmcid">PMC9694640</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Dennen CA, Blum K, Bowirrat A, Thanos PK, Elman I, Ceccanti M, Badgaiyan RD, McLaughlin T, Gupta A, Bajaj A (2022) Genetic addiction risk severity assessment identifies polymorphic reward genes as antecedents to reward deficiency syndrome (RDS) hypodopaminergia&#8217;s effect on addictive and non-addictive behaviors in a nuclear family. J Pers Med 12(11):1864. 10.3390/jpm12111864<pub-id pub-id-type="pmid">36579592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm12111864</pub-id><pub-id pub-id-type="pmcid">PMC9694640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Downs</surname><given-names>BW</given-names></name><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>Bowirrat</surname><given-names>A</given-names></name><name name-style="western"><surname>Lott</surname><given-names>L</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>R</given-names></name><name name-style="western"><surname>Boyett</surname><given-names>B</given-names></name><name name-style="western"><surname>Siwicki</surname><given-names>D</given-names></name><name name-style="western"><surname>Roy</surname><given-names>AK</given-names></name><name name-style="western"><surname>Podesta</surname><given-names>A</given-names></name></person-group><article-title>Death by opioids: are there non-addictive scientific solutions?</article-title><source>J Syst Integr Neurosci</source><year>2019</year><pub-id pub-id-type="doi">10.15761/JSIN.1000211</pub-id><pub-id pub-id-type="pmid">31824737</pub-id><pub-id pub-id-type="pmcid">PMC6904107</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Downs BW, Blum K, Baron D, Bowirrat A, Lott L, Brewer R, Boyett B, Siwicki D, Roy AK, Podesta A (2019) Death by opioids: are there non-addictive scientific solutions? J Syst Integr Neurosci. 10.15761/JSIN.1000211<pub-id pub-id-type="pmid">31824737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15761/JSIN.1000211</pub-id><pub-id pub-id-type="pmcid">PMC6904107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dufour</surname><given-names>R</given-names></name><name name-style="western"><surname>Mardekian</surname><given-names>J</given-names></name><name name-style="western"><surname>Pasquale</surname><given-names>MK</given-names></name><name name-style="western"><surname>Schaaf</surname><given-names>D</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>GA</given-names></name><name name-style="western"><surname>Patel</surname><given-names>NC</given-names></name></person-group><article-title>Understanding predictors of opioid abuse: predictive model development and validation</article-title><source>Am J Pharm Benefits</source><year>2014</year><volume>6</volume><issue>5</issue><fpage>208</fpage><lpage>216</lpage></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Dufour R, Mardekian J, Pasquale MK, Schaaf D, Andrews GA, Patel NC (2014) Understanding predictors of opioid abuse: predictive model development and validation. Am J Pharm Benefits 6(5):208&#8211;216</mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Ibrahimi</surname><given-names>S</given-names></name><name name-style="western"><surname>Hendricks</surname><given-names>MA</given-names></name><name name-style="western"><surname>Little</surname><given-names>K</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>GA</given-names></name><name name-style="western"><surname>Flores</surname><given-names>D</given-names></name><name name-style="western"><surname>Loy</surname><given-names>B</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>SG</given-names></name></person-group><article-title>The association between community social vulnerability and prescription opioid availability with individual opioid overdose</article-title><source>Drug Alcohol Depend</source><year>2023</year><volume>252</volume><fpage>110991</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2023.110991</pub-id><pub-id pub-id-type="pmid">37862877</pub-id><pub-id pub-id-type="pmcid">PMC10754350</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">El Ibrahimi S, Hendricks MA, Little K, Ritter GA, Flores D, Loy B, Wright D, Weiner SG (2023) The association between community social vulnerability and prescription opioid availability with individual opioid overdose. Drug Alcohol Depend 252:110991. 10.1016/j.drugalcdep.2023.110991<pub-id pub-id-type="pmid">37862877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2023.110991</pub-id><pub-id pub-id-type="pmcid">PMC10754350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ettienne</surname><given-names>EB</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>E</given-names></name><name name-style="western"><surname>Maneno</surname><given-names>M</given-names></name><name name-style="western"><surname>Ofoegbu</surname><given-names>A</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>B</given-names></name><name name-style="western"><surname>Settles-Reaves</surname><given-names>B</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>M</given-names></name><name name-style="western"><surname>Dunston</surname><given-names>G</given-names></name><name name-style="western"><surname>Rosenblatt</surname><given-names>K</given-names></name></person-group><article-title>Pharmacogenomics-guided policy in opioid use disorder (OUD) management: an ethnically-diverse case-based approach</article-title><source>Addict Behav Rep</source><year>2017</year><volume>6</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.abrep.2017.05.001</pub-id><pub-id pub-id-type="pmid">29450233</pub-id><pub-id pub-id-type="pmcid">PMC5800559</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ettienne EB, Chapman E, Maneno M, Ofoegbu A, Wilson B, Settles-Reaves B, Clarke M, Dunston G, Rosenblatt K (2017) Pharmacogenomics-guided policy in opioid use disorder (OUD) management: an ethnically-diverse case-based approach. Addict Behav Rep 6:8&#8211;14. 10.1016/j.abrep.2017.05.001<pub-id pub-id-type="pmid">29450233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.abrep.2017.05.001</pub-id><pub-id pub-id-type="pmcid">PMC5800559</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ettienne</surname><given-names>EB</given-names></name><name name-style="western"><surname>Ofoegbu</surname><given-names>A</given-names></name><name name-style="western"><surname>Maneno</surname><given-names>MK</given-names></name><name name-style="western"><surname>Briggs</surname><given-names>J</given-names></name><name name-style="western"><surname>Ezeude</surname><given-names>G</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S</given-names></name><name name-style="western"><surname>Walker</surname><given-names>C</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>E</given-names></name></person-group><article-title>Pharmacogenomics and opioid use disorder: clinical decision support in an African American cohort</article-title><source>J Natl Med Assoc</source><year>2019</year><volume>111</volume><issue>6</issue><fpage>674</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.jnma.2019.09.006</pub-id><pub-id pub-id-type="pmid">31676110</pub-id><pub-id pub-id-type="pmcid">PMC8815013</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ettienne EB, Ofoegbu A, Maneno MK, Briggs J, Ezeude G, Williams S, Walker C, Chapman E (2019) Pharmacogenomics and opioid use disorder: clinical decision support in an African American cohort. J Natl Med Assoc 111(6):674&#8211;681. 10.1016/j.jnma.2019.09.006<pub-id pub-id-type="pmid">31676110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jnma.2019.09.006</pub-id><pub-id pub-id-type="pmcid">PMC8815013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fried</surname><given-names>L</given-names></name><name name-style="western"><surname>Modestino</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Siwicki</surname><given-names>D</given-names></name><name name-style="western"><surname>Lott</surname><given-names>L</given-names></name><name name-style="western"><surname>Thanos</surname><given-names>PK</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>Badgaiyan</surname><given-names>RD</given-names></name><name name-style="western"><surname>Ponce</surname><given-names>JV</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>J</given-names></name><name name-style="western"><surname>Downs</surname><given-names>WB</given-names></name></person-group><article-title>Hypodopaminergia and &#8220;Precision Behavioral Management&#8221; (PBM): it is a generational family affair</article-title><source>Curr Pharm Biotechnol</source><year>2020</year><volume>21</volume><issue>6</issue><fpage>528</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.2174/1389201021666191210112108</pub-id><pub-id pub-id-type="pmid">31820688</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Fried L, Modestino EJ, Siwicki D, Lott L, Thanos PK, Baron D, Badgaiyan RD, Ponce JV, Giordano J, Downs WB (2020) Hypodopaminergia and &#8220;Precision Behavioral Management&#8221; (PBM): it is a generational family affair. Curr Pharm Biotechnol 21(6):528&#8211;541. 10.2174/1389201021666191210112108<pub-id pub-id-type="pmid">31820688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389201021666191210112108</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>N</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>DC</given-names></name><name name-style="western"><surname>Mateu-Gelabert</surname><given-names>P</given-names></name><name name-style="western"><surname>Ompad</surname><given-names>DC</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>L</given-names></name><name name-style="western"><surname>Nikolopoulos</surname><given-names>G</given-names></name><name name-style="western"><surname>Guarino</surname><given-names>H</given-names></name><name name-style="western"><surname>Cerd&#225;</surname><given-names>M</given-names></name></person-group><article-title>The opioid/overdose crisis as a dialectics of pain, despair, and one-sided struggle</article-title><source>Front Public Health</source><year>2020</year><volume>8</volume><fpage>540423</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2020.540423</pub-id><pub-id pub-id-type="pmid">33251171</pub-id><pub-id pub-id-type="pmcid">PMC7676222</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Friedman SR, Krawczyk N, Perlman DC, Mateu-Gelabert P, Ompad DC, Hamilton L, Nikolopoulos G, Guarino H, Cerd&#225; M (2020) The opioid/overdose crisis as a dialectics of pain, despair, and one-sided struggle. Front Public Health 8:540423. 10.3389/fpubh.2020.540423<pub-id pub-id-type="pmid">33251171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2020.540423</pub-id><pub-id pub-id-type="pmcid">PMC7676222</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukuda</surname><given-names>K</given-names></name><name name-style="western"><surname>Hayashida</surname><given-names>M</given-names></name><name name-style="western"><surname>Ide</surname><given-names>S</given-names></name><name name-style="western"><surname>Saita</surname><given-names>N</given-names></name><name name-style="western"><surname>Kokita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kasai</surname><given-names>S</given-names></name><name name-style="western"><surname>Nishizawa</surname><given-names>D</given-names></name><name name-style="western"><surname>Ogai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>J</given-names></name><name name-style="western"><surname>Nagashima</surname><given-names>M</given-names></name></person-group><article-title>Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery</article-title><source>PAIN&#174;</source><year>2009</year><volume>147</volume><issue>1&#8211;3</issue><fpage>194</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2009.09.004</pub-id><pub-id pub-id-type="pmid">19783098</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Fukuda K, Hayashida M, Ide S, Saita N, Kokita Y, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Nagashima M (2009) Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. PAIN&#174; 147(1&#8211;3):194&#8211;201. 10.1016/j.pain.2009.09.004<pub-id pub-id-type="pmid">19783098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2009.09.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galetta</surname><given-names>MS</given-names></name><name name-style="western"><surname>Leider</surname><given-names>JD</given-names></name><name name-style="western"><surname>Divi</surname><given-names>SN</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>DKC</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>GD</given-names></name></person-group><article-title>Robotics in spinal surgery</article-title><source>Ann Transl Med</source><year>2019</year><volume>7</volume><issue>Suppl 5</issue><fpage>S165</fpage><pub-id pub-id-type="doi">10.21037/atm.2019.07.93</pub-id><pub-id pub-id-type="pmid">31624731</pub-id><pub-id pub-id-type="pmcid">PMC6778279</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Galetta MS, Leider JD, Divi SN, Goyal DKC, Schroeder GD (2019) Robotics in spinal surgery. Ann Transl Med 7(Suppl 5):S165. 10.21037/atm.2019.07.93<pub-id pub-id-type="pmid">31624731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm.2019.07.93</pub-id><pub-id pub-id-type="pmcid">PMC6778279</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Leighton</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J</given-names></name><name name-style="western"><surname>Mistry</surname><given-names>P</given-names></name></person-group><article-title>Predicting opioid use disorder and associated risk factors in a Medicaid managed care population</article-title><source>Am J Manag Care</source><year>2021</year><pub-id pub-id-type="doi">10.37765/ajmc.2021.88617</pub-id><pub-id pub-id-type="pmid">33877773</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Gao W, Leighton C, Chen Y, Jones J, Mistry P (2021) Predicting opioid use disorder and associated risk factors in a Medicaid managed care population. Am J Manag Care. 10.37765/ajmc.2021.88617<pub-id pub-id-type="pmid">33877773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.37765/ajmc.2021.88617</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gondr&#233;-Lewis</surname><given-names>MC</given-names></name><name name-style="western"><surname>Elman</surname><given-names>I</given-names></name><name name-style="western"><surname>Alim</surname><given-names>T</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>E</given-names></name><name name-style="western"><surname>Settles-Reaves</surname><given-names>B</given-names></name><name name-style="western"><surname>Galvao</surname><given-names>C</given-names></name><name name-style="western"><surname>Gold</surname><given-names>MS</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>S</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>E</given-names></name></person-group><article-title>Frequency of the dopamine receptor D3 (rs6280) vs. opioid receptor &#181;1 (rs1799971) polymorphic risk alleles in patients with opioid use disorder: a preponderance of dopaminergic mechanisms?</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><issue>4</issue><fpage>870</fpage><pub-id pub-id-type="doi">10.3390/biomedicines10040870</pub-id><pub-id pub-id-type="pmid">35453620</pub-id><pub-id pub-id-type="pmcid">PMC9027142</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Gondr&#233;-Lewis MC, Elman I, Alim T, Chapman E, Settles-Reaves B, Galvao C, Gold MS, Baron D, Kazmi S, Gardner E (2022) Frequency of the dopamine receptor D3 (rs6280) vs. opioid receptor &#181;1 (rs1799971) polymorphic risk alleles in patients with opioid use disorder: a preponderance of dopaminergic mechanisms? Biomedicines 10(4):870. 10.3390/biomedicines10040870<pub-id pub-id-type="pmid">35453620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10040870</pub-id><pub-id pub-id-type="pmcid">PMC9027142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Bowirrat</surname><given-names>A</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>LL</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name><name name-style="western"><surname>Elman</surname><given-names>I</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>J</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>R</given-names></name><name name-style="western"><surname>Badgaiyan</surname><given-names>RD</given-names></name><name name-style="western"><surname>Modestino</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Gold</surname><given-names>MS</given-names></name></person-group><article-title>Hypothesizing in the face of the opioid crisis coupling Genetic Addiction Risk Severity (GARS) testing with electrotherapeutic nonopioid modalities such as H-Wave could attenuate both pain and hedonic addictive behaviors</article-title><source>Int J Environ Res Public Health</source><year>2022</year><volume>19</volume><issue>1</issue><fpage>552</fpage><pub-id pub-id-type="doi">10.3390/ijerph19010552</pub-id><pub-id pub-id-type="pmid">35010811</pub-id><pub-id pub-id-type="pmcid">PMC8744782</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Gupta A, Bowirrat A, Gomez LL, Baron D, Elman I, Giordano J, Jalali R, Badgaiyan RD, Modestino EJ, Gold MS (2022) Hypothesizing in the face of the opioid crisis coupling Genetic Addiction Risk Severity (GARS) testing with electrotherapeutic nonopioid modalities such as H-Wave could attenuate both pain and hedonic addictive behaviors. Int J Environ Res Public Health 19(1):552<pub-id pub-id-type="pmid">35010811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph19010552</pub-id><pub-id pub-id-type="pmcid">PMC8744782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><mixed-citation publication-type="other">Hayashida M, Nagashima M, Satoh Y, Katoh R, Tagami M, Ide S, Kasai S, Nishizawa D, Ogai Y, Hasegawa J (2008) Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. 10.2217/14622416.9.11.1605<pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/14622416.9.11.1605</pub-id><pub-id pub-id-type="pmid">19018716</pub-id></mixed-citation></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>McNutt</surname><given-names>MA</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>Simian immunodeficiency virus impacts microRNA-16 mediated post-transcriptional regulation of mu opioid receptor in CEM &#215;174 cells</article-title><source>J Cell Biochem</source><year>2016</year><volume>117</volume><issue>1</issue><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1002/jcb.25251</pub-id><pub-id pub-id-type="pmid">26052934</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Hou W, Li H, Jiang W, Zhang C, McNutt MA, Li G (2016a) Simian immunodeficiency virus impacts microRNA-16 mediated post-transcriptional regulation of mu opioid receptor in CEM &#215;174 cells. J Cell Biochem 117(1):84&#8211;93. 10.1002/jcb.25251<pub-id pub-id-type="pmid">26052934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.25251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>McNutt</surname><given-names>MA</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>Simian immunodeficiency virus impacts microRNA-16 mediated post-transcriptional regulation of mu opioid receptor in CEM&#215; 174 cells</article-title><source>J Cell Biochem</source><year>2016</year><volume>117</volume><issue>1</issue><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1002/jcb.25251</pub-id><pub-id pub-id-type="pmid">26052934</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Hou W, Li H, Jiang W, Zhang C, McNutt MA, Li G (2016b) Simian immunodeficiency virus impacts microRNA-16 mediated post-transcriptional regulation of mu opioid receptor in CEM&#215; 174 cells. J Cell Biochem 117(1):84&#8211;93. 10.1002/jcb.25251<pub-id pub-id-type="pmid">26052934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.25251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janicki</surname><given-names>PK</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>G</given-names></name><name name-style="western"><surname>Francis</surname><given-names>D</given-names></name><name name-style="western"><surname>Bohr</surname><given-names>A</given-names></name><name name-style="western"><surname>Gordin</surname><given-names>V</given-names></name><name name-style="western"><surname>Jarzembowski</surname><given-names>T</given-names></name><name name-style="western"><surname>Ruiz-Velasco</surname><given-names>V</given-names></name><name name-style="western"><surname>Mets</surname><given-names>B</given-names></name></person-group><article-title>A genetic association study of the functional A118G polymorphism of the human &#956;-opioid receptor gene in patients with acute and chronic pain</article-title><source>Anesth Analg</source><year>2006</year><volume>103</volume><issue>4</issue><fpage>1011</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1213/01.ane.0000231634.20341.88</pub-id><pub-id pub-id-type="pmid">17000822</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Janicki PK, Schuler G, Francis D, Bohr A, Gordin V, Jarzembowski T, Ruiz-Velasco V, Mets B (2006) A genetic association study of the functional A118G polymorphism of the human &#956;-opioid receptor gene in patients with acute and chronic pain. Anesth Analg 103(4):1011&#8211;1017. 10.1213/01.ane.0000231634.20341.88<pub-id pub-id-type="pmid">17000822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/01.ane.0000231634.20341.88</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Clark</surname><given-names>D</given-names></name><name name-style="western"><surname>Dionne</surname><given-names>RA</given-names></name></person-group><article-title>Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research</article-title><source>J Pain</source><year>2009</year><volume>10</volume><issue>7</issue><fpage>663</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2009.04.001</pub-id><pub-id pub-id-type="pmid">19559388</pub-id><pub-id pub-id-type="pmcid">PMC2999357</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kim H, Clark D, Dionne RA (2009) Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J Pain 10(7):663&#8211;693. 10.1016/j.jpain.2009.04.001<pub-id pub-id-type="pmid">19559388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2009.04.001</pub-id><pub-id pub-id-type="pmcid">PMC2999357</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krauss</surname><given-names>WE</given-names></name><name name-style="western"><surname>Habermann</surname><given-names>EB</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>A</given-names></name><name name-style="western"><surname>Ubl</surname><given-names>DS</given-names></name><name name-style="western"><surname>Alvi</surname><given-names>MA</given-names></name><name name-style="western"><surname>Whipple</surname><given-names>DC</given-names></name><name name-style="western"><surname>Glasgow</surname><given-names>AE</given-names></name><name name-style="western"><surname>Gazelka</surname><given-names>HM</given-names></name><name name-style="western"><surname>Bydon</surname><given-names>M</given-names></name></person-group><article-title>Impact of opioid prescribing guidelines on postoperative opioid prescriptions following elective spine surgery: results from an institutional quality improvement initiative</article-title><source>Neurosurgery</source><year>2021</year><volume>89</volume><issue>3</issue><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1093/neuros/nyab196</pub-id><pub-id pub-id-type="pmid">34114041</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Krauss WE, Habermann EB, Goyal A, Ubl DS, Alvi MA, Whipple DC, Glasgow AE, Gazelka HM, Bydon M (2021) Impact of opioid prescribing guidelines on postoperative opioid prescriptions following elective spine surgery: results from an institutional quality improvement initiative. Neurosurgery 89(3):460&#8211;470. 10.1093/neuros/nyab196<pub-id pub-id-type="pmid">34114041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/neuros/nyab196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kusuda</surname><given-names>R</given-names></name><name name-style="western"><surname>Cadetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Ravanelli</surname><given-names>MI</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>TA</given-names></name><name name-style="western"><surname>Zanon</surname><given-names>S</given-names></name><name name-style="western"><surname>De Lucca</surname><given-names>FL</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>G</given-names></name></person-group><article-title>Differential expression of microRNAs in mouse pain models</article-title><source>Mol Pain</source><year>2011</year><pub-id pub-id-type="doi">10.1186/1744-8069-7-17</pub-id><pub-id pub-id-type="pmid">21385380</pub-id><pub-id pub-id-type="pmcid">PMC3060138</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Kusuda R, Cadetti F, Ravanelli MI, Sousa TA, Zanon S, De Lucca FL, Lucas G (2011) Differential expression of microRNAs in mouse pain models. Mol Pain. 10.1186/1744-8069-7-17<pub-id pub-id-type="pmid">21385380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1744-8069-7-17</pub-id><pub-id pub-id-type="pmcid">PMC3060138</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hakonarson</surname><given-names>H</given-names></name><name name-style="western"><surname>Cook-Sather</surname><given-names>SD</given-names></name></person-group><article-title>Candidate gene analyses for acute pain and morphine analgesia after pediatric day surgery: African American versus European Caucasian ancestry and dose prediction limits</article-title><source>Pharmacogenomics J</source><year>2019</year><volume>19</volume><issue>6</issue><fpage>570</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1038/s41397-019-0074-4</pub-id><pub-id pub-id-type="pmid">30760877</pub-id><pub-id pub-id-type="pmcid">PMC6693985</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Li J, Wei Z, Zhang J, Hakonarson H, Cook-Sather SD (2019a) Candidate gene analyses for acute pain and morphine analgesia after pediatric day surgery: African American versus European Caucasian ancestry and dose prediction limits. Pharmacogenomics J 19(6):570&#8211;581. 10.1038/s41397-019-0074-4<pub-id pub-id-type="pmid">30760877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41397-019-0074-4</pub-id><pub-id pub-id-type="pmcid">PMC6693985</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Tao</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name></person-group><article-title>Inhibition of microRNA-15a/16 expression alleviates neuropathic pain development through upregulation of G protein-coupled receptor kinase 2</article-title><source>Biomol Ther</source><year>2019</year><volume>27</volume><issue>4</issue><fpage>414</fpage><pub-id pub-id-type="doi">10.4062/biomolther.2018.073</pub-id><pub-id pub-id-type="pmcid">PMC6609114</pub-id><pub-id pub-id-type="pmid">31189298</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Li T, Wan Y, Sun L, Tao S, Chen P, Liu C, Wang K, Zhou C, Zhao G (2019b) Inhibition of microRNA-15a/16 expression alleviates neuropathic pain development through upregulation of G protein-coupled receptor kinase 2. Biomol Ther 27(4):414. 10.4062/biomolther.2018.073<pub-id pub-id-type="doi" assigning-authority="pmc">10.4062/biomolther.2018.073</pub-id><pub-id pub-id-type="pmcid">PMC6609114</pub-id><pub-id pub-id-type="pmid">31189298</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>CR</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>HW</given-names></name><name name-style="western"><surname>Sheen-Chen</surname><given-names>SM</given-names></name></person-group><article-title>Intrathecal miR-183 delivery suppresses mechanical allodynia in mononeuropathic rats</article-title><source>Eur J Neurosci</source><year>2014</year><volume>39</volume><issue>10</issue><fpage>1682</fpage><lpage>1689</lpage><pub-id pub-id-type="doi">10.1111/ejn.12522</pub-id><pub-id pub-id-type="pmid">24612023</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Lin CR, Chen KH, Yang CH, Huang HW, Sheen-Chen SM (2014) Intrathecal miR-183 delivery suppresses mechanical allodynia in mononeuropathic rats. Eur J Neurosci 39(10):1682&#8211;1689. 10.1111/ejn.12522<pub-id pub-id-type="pmid">24612023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ejn.12522</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#246;tsch</surname><given-names>J</given-names></name><name name-style="western"><surname>Geisslinger</surname><given-names>G</given-names></name></person-group><article-title>Current evidence for a genetic modulation of the response to analgesics</article-title><source>Pain</source><year>2006</year><volume>121</volume><issue>1&#8211;2</issue><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2006.01.010</pub-id><pub-id pub-id-type="pmid">16472919</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">L&#246;tsch J, Geisslinger G (2006) Current evidence for a genetic modulation of the response to analgesics. Pain 121(1&#8211;2):1&#8211;5. 10.1016/j.pain.2006.01.010<pub-id pub-id-type="pmid">16472919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2006.01.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mamie</surname><given-names>C</given-names></name><name name-style="western"><surname>Rebsamen</surname><given-names>MC</given-names></name><name name-style="western"><surname>Morris</surname><given-names>MA</given-names></name><name name-style="western"><surname>Morabia</surname><given-names>A</given-names></name></person-group><article-title>First evidence of a polygenic susceptibility to pain in a pediatric cohort</article-title><source>Anesth Analg</source><year>2013</year><volume>116</volume><issue>1</issue><fpage>170</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1213/ANE.0b013e31826f0637</pub-id><pub-id pub-id-type="pmid">23223113</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Mamie C, Rebsamen MC, Morris MA, Morabia A (2013) First evidence of a polygenic susceptibility to pain in a pediatric cohort. Anesth Analg 116(1):170&#8211;177. 10.1213/ANE.0b013e31826f0637<pub-id pub-id-type="pmid">23223113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0b013e31826f0637</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manworren</surname><given-names>RC</given-names></name></person-group><article-title>Multimodal pain management and the future of a personalized medicine approach to pain</article-title><source>AORN J</source><year>2015</year><volume>101</volume><issue>3</issue><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/j.aorn.2014.12.009</pub-id><pub-id pub-id-type="pmid">25707723</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Manworren RC (2015) Multimodal pain management and the future of a personalized medicine approach to pain. AORN J 101(3):307&#8211;318. 10.1016/j.aorn.2014.12.009<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.aorn.2014.12.009</pub-id><pub-id pub-id-type="pmid">25707723</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matic</surname><given-names>M</given-names></name><name name-style="western"><surname>de Hoogd</surname><given-names>S</given-names></name><name name-style="western"><surname>de Wildt</surname><given-names>SN</given-names></name><name name-style="western"><surname>Tibboel</surname><given-names>D</given-names></name><name name-style="western"><surname>Knibbe</surname><given-names>CA</given-names></name><name name-style="western"><surname>van Schaik</surname><given-names>RH</given-names></name></person-group><article-title>OPRM1 and COMT polymorphisms: implications on postoperative acute, chronic and experimental pain after cardiac surgery</article-title><source>Pharmacogenomics</source><year>2020</year><volume>21</volume><issue>3</issue><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.2217/pgs-2019-0141</pub-id><pub-id pub-id-type="pmid">31967515</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Matic M, de Hoogd S, de Wildt SN, Tibboel D, Knibbe CA, van Schaik RH (2020) OPRM1 and COMT polymorphisms: implications on postoperative acute, chronic and experimental pain after cardiac surgery. Pharmacogenomics 21(3):181&#8211;193. 10.2217/pgs-2019-0141<pub-id pub-id-type="pmid">31967515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/pgs-2019-0141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McClelland</surname><given-names>S</given-names><suffix>III</suffix></name><name name-style="western"><surname>Goldstein</surname><given-names>JA</given-names></name></person-group><article-title>Minimally invasive versus open spine surgery: what does the best evidence tell us?</article-title><source>J Neurosci Rural Pract</source><year>2017</year><volume>8</volume><issue>2</issue><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.4103/jnrp.jnrp_472_16</pub-id><pub-id pub-id-type="pmid">28479791</pub-id><pub-id pub-id-type="pmcid">PMC5402483</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">McClelland S III, Goldstein JA (2017) Minimally invasive versus open spine surgery: what does the best evidence tell us? J Neurosci Rural Pract 8(2):194&#8211;198. 10.4103/jnrp.jnrp_472_16<pub-id pub-id-type="pmid">28479791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/jnrp.jnrp_472_16</pub-id><pub-id pub-id-type="pmcid">PMC5402483</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><citation-alternatives><element-citation id="ec-CR50" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Meier</surname><given-names>B</given-names></name></person-group><source>Pain killer: a &#8220;wonder&#8221; drug's trail of addiction and death</source><year>2003</year><publisher-loc>Emmaus</publisher-loc><publisher-name>Rodale</publisher-name></element-citation><mixed-citation id="mc-CR50" publication-type="book">Meier B (2003) Pain killer: a &#8220;wonder&#8221; drug&#8217;s trail of addiction and death. Rodale, Emmaus</mixed-citation></citation-alternatives></ref><ref id="CR51"><citation-alternatives><element-citation id="ec-CR51" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Meier</surname><given-names>B</given-names></name></person-group><source>Pain killer: an empire of deceit and the origin of America's opioid epidemic</source><year>2018</year><publisher-loc>New York</publisher-loc><publisher-name>Random House</publisher-name></element-citation><mixed-citation id="mc-CR51" publication-type="book">Meier B (2018) Pain killer: an empire of deceit and the origin of America&#8217;s opioid epidemic. Random House, New York</mixed-citation></citation-alternatives></ref><ref id="CR52"><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>C</given-names></name><name name-style="western"><surname>Goldaraz</surname><given-names>MDLP</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>R</given-names></name><name name-style="western"><surname>Echavarria</surname><given-names>R</given-names></name></person-group><article-title>Novel roles of non-coding RNAs in opioid signaling and cardioprotection</article-title><source>Non-Coding RNA</source><year>2018</year><volume>4</volume><issue>3</issue><fpage>22</fpage><pub-id pub-id-type="doi">10.3390/ncrna4030022</pub-id><pub-id pub-id-type="pmid">30227648</pub-id><pub-id pub-id-type="pmcid">PMC6162605</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Melo Z, Ishida C, Goldaraz MDLP, Rojo R, Echavarria R (2018) Novel roles of non-coding RNAs in opioid signaling and cardioprotection. Non-Coding RNA 4(3):22. 10.3390/ncrna4030022<pub-id pub-id-type="pmid">30227648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ncrna4030022</pub-id><pub-id pub-id-type="pmcid">PMC6162605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merchant</surname><given-names>S</given-names></name><name name-style="western"><surname>Prows</surname><given-names>CA</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sadhasivam</surname><given-names>S</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>V</given-names></name><name name-style="western"><surname>Sturm</surname><given-names>P</given-names></name><name name-style="western"><surname>Chidambaran</surname><given-names>V</given-names></name></person-group><article-title>Association of CYP2D6 genotype predicted phenotypes with oxycodone requirements and side effects in children undergoing surgery</article-title><source>Ann Transl Med</source><year>2022</year><pub-id pub-id-type="doi">10.21037/atm-2022-58</pub-id><pub-id pub-id-type="pmid">36618804</pub-id><pub-id pub-id-type="pmcid">PMC9816853</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Merchant S, Prows CA, Yang F, Ding L, MacDonald J, Zhang X, Sadhasivam S, Garcia V, Sturm P, Chidambaran V (2022) Association of CYP2D6 genotype predicted phenotypes with oxycodone requirements and side effects in children undergoing surgery. Ann Transl Med. 10.21037/atm-2022-58<pub-id pub-id-type="pmid">36618804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm-2022-58</pub-id><pub-id pub-id-type="pmcid">PMC9816853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moran</surname><given-names>M</given-names></name><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Ponce</surname><given-names>JV</given-names></name><name name-style="western"><surname>Lott</surname><given-names>L</given-names></name><name name-style="western"><surname>Gondr&#233;-Lewis</surname><given-names>MC</given-names></name><name name-style="western"><surname>Badgaiyan</surname><given-names>S</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>R</given-names></name><name name-style="western"><surname>Downs</surname><given-names>BW</given-names></name><name name-style="western"><surname>Fynman</surname><given-names>P</given-names></name><name name-style="western"><surname>Weingarten</surname><given-names>A</given-names></name></person-group><article-title>High genetic addiction risk score (GARS) in chronically prescribed severe chronic opioid probands attending multi-pain clinics: an open clinical pilot trial</article-title><source>Mol Neurobiol</source><year>2021</year><volume>58</volume><fpage>3335</fpage><lpage>3346</lpage><pub-id pub-id-type="doi">10.1007/s12035-021-02312-1</pub-id><pub-id pub-id-type="pmid">33683627</pub-id><pub-id pub-id-type="pmcid">PMC8257535</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Moran M, Blum K, Ponce JV, Lott L, Gondr&#233;-Lewis MC, Badgaiyan S, Brewer R, Downs BW, Fynman P, Weingarten A (2021) High genetic addiction risk score (GARS) in chronically prescribed severe chronic opioid probands attending multi-pain clinics: an open clinical pilot trial. Mol Neurobiol 58:3335&#8211;3346. 10.1007/s12035-021-02312-1<pub-id pub-id-type="pmid">33683627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-021-02312-1</pub-id><pub-id pub-id-type="pmcid">PMC8257535</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neifert</surname><given-names>SN</given-names></name><name name-style="western"><surname>Martini</surname><given-names>ML</given-names></name><name name-style="western"><surname>Yuk</surname><given-names>F</given-names></name><name name-style="western"><surname>McNeill</surname><given-names>IT</given-names></name><name name-style="western"><surname>Caridi</surname><given-names>JM</given-names></name><name name-style="western"><surname>Steinberger</surname><given-names>J</given-names></name><name name-style="western"><surname>Oermann</surname><given-names>EK</given-names></name></person-group><article-title>Predicting trends in cervical spinal surgery in the United States from 2020 to 2040</article-title><source>World Neurosurg</source><year>2020</year><volume>141</volume><fpage>e175</fpage><lpage>e181</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2020.05.055</pub-id><pub-id pub-id-type="pmid">32416237</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Neifert SN, Martini ML, Yuk F, McNeill IT, Caridi JM, Steinberger J, Oermann EK (2020) Predicting trends in cervical spinal surgery in the United States from 2020 to 2040. World Neurosurg 141:e175&#8211;e181. 10.1016/j.wneu.2020.05.055<pub-id pub-id-type="pmid">32416237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2020.05.055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orosz</surname><given-names>LD</given-names></name><name name-style="western"><surname>Yamout</surname><given-names>T</given-names></name></person-group><article-title>The opioid crisis as it pertains to spine surgery</article-title><source>J Spine Surg</source><year>2023</year><volume>9</volume><issue>1</issue><fpage>9</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.21037/jss-22-107</pub-id><pub-id pub-id-type="pmid">37038425</pub-id><pub-id pub-id-type="pmcid">PMC10082423</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Orosz LD, Yamout T (2023) The opioid crisis as it pertains to spine surgery. J Spine Surg 9(1):9&#8211;12. 10.21037/jss-22-107<pub-id pub-id-type="pmid">37038425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jss-22-107</pub-id><pub-id pub-id-type="pmcid">PMC10082423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orosz</surname><given-names>LD</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>AE</given-names></name><name name-style="western"><surname>Yamout</surname><given-names>T</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>FR</given-names></name><name name-style="western"><surname>Allen</surname><given-names>B</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>TC</given-names></name><name name-style="western"><surname>Roy</surname><given-names>R</given-names></name><name name-style="western"><surname>Good</surname><given-names>CR</given-names></name><name name-style="western"><surname>Haines</surname><given-names>CM</given-names></name><name name-style="western"><surname>Jazini</surname><given-names>E</given-names></name></person-group><article-title>Opioid use after elective spine surgery: do spine surgery patients consume less than prescribed today?</article-title><source>N Am Spine Soc J</source><year>2022</year><volume>12</volume><fpage>100185</fpage><pub-id pub-id-type="doi">10.1016/j.xnsj.2022.100185</pub-id><pub-id pub-id-type="pmid">36479002</pub-id><pub-id pub-id-type="pmcid">PMC9720562</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Orosz LD, Thomson AE, Yamout T, Bhatt FR, Allen B, Schuler TC, Roy R, Good CR, Haines CM, Jazini E (2022) Opioid use after elective spine surgery: do spine surgery patients consume less than prescribed today? N Am Spine Soc J 12:100185. 10.1016/j.xnsj.2022.100185<pub-id pub-id-type="pmid">36479002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xnsj.2022.100185</pub-id><pub-id pub-id-type="pmcid">PMC9720562</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piper</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Shah</surname><given-names>DT</given-names></name><name name-style="western"><surname>Simoyan</surname><given-names>OM</given-names></name><name name-style="western"><surname>McCall</surname><given-names>KL</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>SD</given-names></name></person-group><article-title>Trends in medical use of opioids in the US, 2006&#8211;2016</article-title><source>Am J Prev Med</source><year>2018</year><volume>54</volume><issue>5</issue><fpage>652</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2018.01.034</pub-id><pub-id pub-id-type="pmid">29551331</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Piper BJ, Shah DT, Simoyan OM, McCall KL, Nichols SD (2018) Trends in medical use of opioids in the US, 2006&#8211;2016. Am J Prev Med 54(5):652&#8211;660. 10.1016/j.amepre.2018.01.034<pub-id pub-id-type="pmid">29551331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2018.01.034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><citation-alternatives><element-citation id="ec-CR59" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Posner</surname><given-names>G</given-names></name></person-group><source>Pharma: greed, lies, and the poisoning of America</source><year>2021</year><publisher-loc>New York</publisher-loc><publisher-name>Simon and Schuster</publisher-name></element-citation><mixed-citation id="mc-CR59" publication-type="book">Posner G (2021) Pharma: greed, lies, and the poisoning of America. Simon and Schuster, New York</mixed-citation></citation-alternatives></ref><ref id="CR60"><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prashant</surname><given-names>H</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>KN</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>S</given-names></name><name name-style="western"><surname>Wadhwa</surname><given-names>B</given-names></name><name name-style="western"><surname>Kerai</surname><given-names>S</given-names></name><name name-style="western"><surname>Gaba</surname><given-names>P</given-names></name></person-group><article-title>Correlation of pain perception and fentanyl consumption after major abdominal surgery with CGRP 4218T/C polymorphism: a prospective interventional study</article-title><source>Indian J Anaesth</source><year>2023</year><volume>67</volume><issue>9</issue><fpage>796</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.4103/ija.ija_1033_22</pub-id><pub-id pub-id-type="pmid">37829781</pub-id><pub-id pub-id-type="pmcid">PMC10566653</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Prashant H, Saxena KN, Kapoor S, Wadhwa B, Kerai S, Gaba P (2023) Correlation of pain perception and fentanyl consumption after major abdominal surgery with CGRP 4218T/C polymorphism: a prospective interventional study. Indian J Anaesth 67(9):796&#8211;801. 10.4103/ija.ija_1033_22<pub-id pub-id-type="pmid">37829781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ija.ija_1033_22</pub-id><pub-id pub-id-type="pmcid">PMC10566653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rocco</surname><given-names>R</given-names></name><name name-style="western"><surname>Thiels</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ubl</surname><given-names>DS</given-names></name><name name-style="western"><surname>Moyer</surname><given-names>AM</given-names></name><name name-style="western"><surname>Habermann</surname><given-names>EB</given-names></name><name name-style="western"><surname>Cassivi</surname><given-names>SD</given-names></name></person-group><article-title>Use of pharmacogenetic data to guide individualized opioid prescribing after surgery</article-title><source>Surgery</source><year>2019</year><volume>166</volume><issue>4</issue><fpage>476</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2019.04.033</pub-id><pub-id pub-id-type="pmid">31320226</pub-id><pub-id pub-id-type="pmcid">PMC7089776</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Rocco R, Thiels CA, Ubl DS, Moyer AM, Habermann EB, Cassivi SD (2019) Use of pharmacogenetic data to guide individualized opioid prescribing after surgery. Surgery 166(4):476&#8211;482. 10.1016/j.surg.2019.04.033<pub-id pub-id-type="pmid">31320226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.surg.2019.04.033</pub-id><pub-id pub-id-type="pmcid">PMC7089776</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadhasivam</surname><given-names>S</given-names></name><name name-style="western"><surname>Chidambaran</surname><given-names>V</given-names></name></person-group><article-title>Pharmacogenomics of opioids and perioperative pain management</article-title><source>Pharmacogenomics</source><year>2012</year><volume>13</volume><issue>15</issue><fpage>1719</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.2217/pgs.12.152</pub-id><pub-id pub-id-type="pmid">23171337</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Sadhasivam S, Chidambaran V (2012) Pharmacogenomics of opioids and perioperative pain management. Pharmacogenomics 13(15):1719&#8211;1740. 10.2217/pgs.12.152<pub-id pub-id-type="pmid">23171337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/pgs.12.152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarpatwari</surname><given-names>A</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>MS</given-names></name><name name-style="western"><surname>Kesselheim</surname><given-names>AS</given-names></name></person-group><article-title>The opioid epidemic: fixing a broken pharmaceutical market</article-title><source>Harv Law Policy Rev</source><year>2017</year><volume>11</volume><fpage>463</fpage></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Sarpatwari A, Sinha MS, Kesselheim AS (2017) The opioid epidemic: fixing a broken pharmaceutical market. Harv Law Policy Rev 11:463</mixed-citation></citation-alternatives></ref><ref id="CR64"><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scher</surname><given-names>C</given-names></name><name name-style="western"><surname>Meador</surname><given-names>L</given-names></name><name name-style="western"><surname>Van Cleave</surname><given-names>JH</given-names></name><name name-style="western"><surname>Reid</surname><given-names>MC</given-names></name></person-group><article-title>Moving beyond pain as the fifth vital sign and patient satisfaction scores to improve pain care in the 21st century</article-title><source>Pain Manag Nurs</source><year>2018</year><volume>19</volume><issue>2</issue><fpage>125</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.pmn.2017.10.010</pub-id><pub-id pub-id-type="pmid">29249620</pub-id><pub-id pub-id-type="pmcid">PMC5878703</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Scher C, Meador L, Van Cleave JH, Reid MC (2018) Moving beyond pain as the fifth vital sign and patient satisfaction scores to improve pain care in the 21st century. Pain Manag Nurs 19(2):125&#8211;129. 10.1016/j.pmn.2017.10.010<pub-id pub-id-type="pmid">29249620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pmn.2017.10.010</pub-id><pub-id pub-id-type="pmcid">PMC5878703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>RH</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>TA</given-names></name><name name-style="western"><surname>Caulfield</surname><given-names>M</given-names></name></person-group><article-title>Genomic medicine: time for health-care transformation</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10197</issue><fpage>454</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31796-9</pub-id><pub-id pub-id-type="pmid">31395438</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Scott RH, Fowler TA, Caulfield M (2019) Genomic medicine: time for health-care transformation. Lancet 394(10197):454&#8211;456. 10.1016/S0140-6736(19)31796-9<pub-id pub-id-type="pmid">31395438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)31796-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senagore</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Champagne</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Dosokey</surname><given-names>E</given-names></name><name name-style="western"><surname>Brady</surname><given-names>J</given-names></name><name name-style="western"><surname>Steele</surname><given-names>SR</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>HL</given-names></name><name name-style="western"><surname>Stein</surname><given-names>SL</given-names></name><name name-style="western"><surname>Delaney</surname><given-names>CP</given-names></name></person-group><article-title>Pharmacogenetics-guided analgesics in major abdominal surgery: further benefits within an enhanced recovery protocol</article-title><source>Am J Surg</source><year>2017</year><volume>213</volume><issue>3</issue><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.amjsurg.2016.11.008</pub-id><pub-id pub-id-type="pmid">27955884</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Senagore AJ, Champagne BJ, Dosokey E, Brady J, Steele SR, Reynolds HL, Stein SL, Delaney CP (2017) Pharmacogenetics-guided analgesics in major abdominal surgery: further benefits within an enhanced recovery protocol. Am J Surg 213(3):467&#8211;472. 10.1016/j.amjsurg.2016.11.008<pub-id pub-id-type="pmid">27955884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjsurg.2016.11.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>HS</given-names></name></person-group><article-title>Opioid metabolism</article-title><source>Mayo Clinic Proc</source><year>2009</year><pub-id pub-id-type="doi">10.1016/S0025-6196(11)60750-7</pub-id><pub-id pub-id-type="pmcid">PMC2704133</pub-id><pub-id pub-id-type="pmid">19567715</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Smith HS (2009) Opioid metabolism. Mayo Clinic Proc. 10.1016/S0025-6196(11)60750-7<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0025-6196(11)60750-7</pub-id><pub-id pub-id-type="pmcid">PMC2704133</pub-id><pub-id pub-id-type="pmid">19567715</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snyder</surname><given-names>LA</given-names></name></person-group><article-title>Integrating robotics into a minimally invasive transforaminal interbody fusion workflow</article-title><source>Neurosurg Focus</source><year>2018</year><volume>45</volume><issue>VideoSuppl1</issue><fpage>V4</fpage><pub-id pub-id-type="doi">10.3171/2018.7.FocusVid.18111</pub-id><pub-id pub-id-type="pmid">29963914</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Snyder LA (2018) Integrating robotics into a minimally invasive transforaminal interbody fusion workflow. Neurosurg Focus 45(VideoSuppl1):V4. 10.3171/2018.7.FocusVid.18111<pub-id pub-id-type="pmid">29963914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2018.7.FocusVid.18111</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name></person-group><article-title>Overexpression of miR-206 ameliorates chronic constriction injury-induced neuropathic pain in rats via the MEK/ERK pathway by targeting brain-derived neurotrophic factor</article-title><source>Neurosci Lett</source><year>2017</year><volume>646</volume><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2016.12.047</pub-id><pub-id pub-id-type="pmid">28130187</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Sun W, Zhang L, Li R (2017) Overexpression of miR-206 ameliorates chronic constriction injury-induced neuropathic pain in rats via the MEK/ERK pathway by targeting brain-derived neurotrophic factor. Neurosci Lett 646:68&#8211;74. 10.1016/j.neulet.2016.12.047<pub-id pub-id-type="pmid">28130187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2016.12.047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thanos</surname><given-names>PK</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>C</given-names></name><name name-style="western"><surname>Mihalkovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>A</given-names></name><name name-style="western"><surname>Posner</surname><given-names>A</given-names></name><name name-style="western"><surname>Butsch</surname><given-names>J</given-names></name><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Georger</surname><given-names>L</given-names></name><name name-style="western"><surname>Mastrandrea</surname><given-names>LD</given-names></name><name name-style="western"><surname>Quattrin</surname><given-names>T</given-names></name></person-group><article-title>Genetic correlates as a predictor of bariatric surgery outcomes after 1 year</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><issue>10</issue><fpage>2644</fpage><pub-id pub-id-type="doi">10.3390/biomedicines11102644</pub-id><pub-id pub-id-type="pmid">37893019</pub-id><pub-id pub-id-type="pmcid">PMC10603884</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Thanos PK, Hanna C, Mihalkovic A, Hoffman A, Posner A, Butsch J, Blum K, Georger L, Mastrandrea LD, Quattrin T (2023a) Genetic correlates as a predictor of bariatric surgery outcomes after 1 year. Biomedicines 11(10):2644. 10.3390/biomedicines11102644<pub-id pub-id-type="pmid">37893019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines11102644</pub-id><pub-id pub-id-type="pmcid">PMC10603884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thanos</surname><given-names>PK</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>C</given-names></name><name name-style="western"><surname>Mihalkovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>AB</given-names></name><name name-style="western"><surname>Posner</surname><given-names>AR</given-names></name><name name-style="western"><surname>Busch</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C</given-names></name><name name-style="western"><surname>Badgaiyan</surname><given-names>RD</given-names></name><name name-style="western"><surname>Blum</surname><given-names>K</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D</given-names></name></person-group><article-title>The first exploratory personalized medicine approach to improve bariatric surgery outcomes utilizing psychosocial and genetic risk assessments: encouraging clinical research</article-title><source>J Pers Med</source><year>2023</year><volume>13</volume><issue>7</issue><fpage>1164</fpage><pub-id pub-id-type="doi">10.3390/jpm13071164</pub-id><pub-id pub-id-type="pmid">37511777</pub-id><pub-id pub-id-type="pmcid">PMC10381606</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Thanos PK, Hanna C, Mihalkovic A, Hoffman AB, Posner AR, Busch J, Smith C, Badgaiyan RD, Blum K, Baron D (2023b) The first exploratory personalized medicine approach to improve bariatric surgery outcomes utilizing psychosocial and genetic risk assessments: encouraging clinical research. J Pers Med 13(7):1164. 10.3390/jpm13071164<pub-id pub-id-type="pmid">37511777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm13071164</pub-id><pub-id pub-id-type="pmcid">PMC10381606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Kiyosawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>H</given-names></name></person-group><article-title>Identification of circulating miRNAs differentially regulated by opioid treatment</article-title><source>Int J Mol Sci</source><year>2017</year><volume>18</volume><issue>9</issue><fpage>1991</fpage><pub-id pub-id-type="doi">10.3390/ijms18091991</pub-id><pub-id pub-id-type="pmid">28926935</pub-id><pub-id pub-id-type="pmcid">PMC5618640</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Toyama K, Kiyosawa N, Watanabe K, Ishizuka H (2017) Identification of circulating miRNAs differentially regulated by opioid treatment. Int J Mol Sci 18(9):1991. 10.3390/ijms18091991<pub-id pub-id-type="pmid">28926935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms18091991</pub-id><pub-id pub-id-type="pmcid">PMC5618640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vereczkei</surname><given-names>A</given-names></name><name name-style="western"><surname>Barta</surname><given-names>C</given-names></name><name name-style="western"><surname>Magi</surname><given-names>A</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>J</given-names></name><name name-style="western"><surname>Eisinger</surname><given-names>A</given-names></name><name name-style="western"><surname>Kir&#225;ly</surname><given-names>O</given-names></name><name name-style="western"><surname>Belik</surname><given-names>A</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>MD</given-names></name><name name-style="western"><surname>Szekely</surname><given-names>A</given-names></name><name name-style="western"><surname>Sasv&#225;ri-Sz&#233;kely</surname><given-names>M</given-names></name></person-group><article-title>FOXN3 and GDNF polymorphisms as common genetic factors of substance use and addictive behaviors</article-title><source>J Pers Med</source><year>2022</year><volume>12</volume><issue>5</issue><fpage>690</fpage><pub-id pub-id-type="doi">10.3390/jpm12050690</pub-id><pub-id pub-id-type="pmid">35629112</pub-id><pub-id pub-id-type="pmcid">PMC9144496</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Vereczkei A, Barta C, Magi A, Farkas J, Eisinger A, Kir&#225;ly O, Belik A, Griffiths MD, Szekely A, Sasv&#225;ri-Sz&#233;kely M (2022) FOXN3 and GDNF polymorphisms as common genetic factors of substance use and addictive behaviors. J Pers Med 12(5):690. 10.3390/jpm12050690<pub-id pub-id-type="pmid">35629112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm12050690</pub-id><pub-id pub-id-type="pmcid">PMC9144496</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>MY</given-names></name><name name-style="western"><surname>Tessitore</surname><given-names>E</given-names></name><name name-style="western"><surname>Berrington</surname><given-names>N</given-names></name><name name-style="western"><surname>Dailey</surname><given-names>A</given-names></name></person-group><article-title>Introduction. Enhanced recovery after surgery (ERAS) in spine</article-title><source>Neurosurg Focus</source><year>2019</year><volume>46</volume><issue>4</issue><fpage>E1</fpage><pub-id pub-id-type="doi">10.3171/2019.1.FOCUS1957</pub-id><pub-id pub-id-type="pmid">30933910</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Wang MY, Tessitore E, Berrington N, Dailey A (2019) Introduction. Enhanced recovery after surgery (ERAS) in spine. Neurosurg Focus 46(4):E1. 10.3171/2019.1.FOCUS1957<pub-id pub-id-type="pmid">30933910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2019.1.FOCUS1957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hong</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hong</surname><given-names>BY</given-names></name><name name-style="western"><surname>Couban</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Juurlink</surname><given-names>DN</given-names></name><name name-style="western"><surname>Busse</surname><given-names>JW</given-names></name></person-group><article-title>Predictors of fatal and nonfatal overdose after prescription of opioids for chronic pain: a systematic review and meta-analysis of observational studies</article-title><source>CMAJ</source><year>2023</year><volume>195</volume><issue>41</issue><fpage>E1399</fpage><lpage>E1411</lpage><pub-id pub-id-type="doi">10.1503/cmaj.230459</pub-id><pub-id pub-id-type="pmid">37871953</pub-id><pub-id pub-id-type="pmcid">PMC10593195</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Wang L, Hong PJ, Jiang W, Rehman Y, Hong BY, Couban RJ, Wang C, Hayes CJ, Juurlink DN, Busse JW (2023) Predictors of fatal and nonfatal overdose after prescription of opioids for chronic pain: a systematic review and meta-analysis of observational studies. CMAJ 195(41):E1399&#8211;E1411. 10.1503/cmaj.230459<pub-id pub-id-type="pmid">37871953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.230459</pub-id><pub-id pub-id-type="pmcid">PMC10593195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>N</given-names></name><name name-style="western"><surname>Kariisa</surname><given-names>M</given-names></name><name name-style="western"><surname>Seth</surname><given-names>P</given-names></name><name name-style="western"><surname>Smith</surname><given-names>HT</given-names></name><name name-style="western"><surname>Davis</surname><given-names>NL</given-names></name></person-group><article-title>Drug and opioid-involved overdose deaths&#8212;United States, 2017&#8211;2018</article-title><source>Morb Mortal Wkly Rep</source><year>2020</year><volume>69</volume><issue>11</issue><fpage>290</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6911a4</pub-id><pub-id pub-id-type="pmcid">PMC7739981</pub-id><pub-id pub-id-type="pmid">32191688</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Wilson N, Kariisa M, Seth P, Smith HT, Davis NL (2020) Drug and opioid-involved overdose deaths&#8212;United States, 2017&#8211;2018. Morb Mortal Wkly Rep 69(11):290&#8211;297. 10.15585/mmwr.mm6911a4<pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6911a4</pub-id><pub-id pub-id-type="pmcid">PMC7739981</pub-id><pub-id pub-id-type="pmid">32191688</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>A</given-names></name><name name-style="western"><surname>March</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Blyth</surname><given-names>FM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>R</given-names></name><name name-style="western"><surname>Hoy</surname><given-names>D</given-names></name></person-group><article-title>Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017</article-title><source>Ann Transl Med</source><year>2020</year><volume>8</volume><issue>6</issue><fpage>299</fpage><pub-id pub-id-type="doi">10.21037/atm.2020.02.175</pub-id><pub-id pub-id-type="pmid">32355743</pub-id><pub-id pub-id-type="pmcid">PMC7186678</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Wu A, March L, Zheng X, Huang J, Wang X, Zhao J, Blyth FM, Smith E, Buchbinder R, Hoy D (2020) Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med 8(6):299. 10.21037/atm.2020.02.175<pub-id pub-id-type="pmid">32355743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm.2020.02.175</pub-id><pub-id pub-id-type="pmcid">PMC7186678</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyles</surname><given-names>CC</given-names></name><name name-style="western"><surname>Thiels</surname><given-names>CA</given-names></name><name name-style="western"><surname>Hevesi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ubl</surname><given-names>DS</given-names></name><name name-style="western"><surname>Gazelka</surname><given-names>HM</given-names></name><name name-style="western"><surname>Turner</surname><given-names>NS</given-names><suffix>III</suffix></name><name name-style="western"><surname>Trousdale</surname><given-names>RT</given-names></name><name name-style="western"><surname>Pagnano</surname><given-names>MW</given-names></name><name name-style="western"><surname>Mabry</surname><given-names>TM</given-names></name><name name-style="western"><surname>Habermann</surname><given-names>EB</given-names></name></person-group><article-title>Patient opioid requirements are often far less than their discharge prescription after orthopaedic surgery: the results of a prospective multicenter survey</article-title><source>J Am Acad Orthop Surg</source><year>2021</year><volume>29</volume><issue>7</issue><fpage>e345</fpage><lpage>e353</lpage><pub-id pub-id-type="doi">10.5435/JAAOS-D-19-00415</pub-id><pub-id pub-id-type="pmid">32925379</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Wyles CC, Thiels CA, Hevesi M, Ubl DS, Gazelka HM, Turner NS III, Trousdale RT, Pagnano MW, Mabry TM, Habermann EB (2021) Patient opioid requirements are often far less than their discharge prescription after orthopaedic surgery: the results of a prospective multicenter survey. J Am Acad Orthop Surg 29(7):e345&#8211;e353. 10.5435/JAAOS-D-19-00415<pub-id pub-id-type="pmid">32925379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5435/JAAOS-D-19-00415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Xi</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Fan</surname><given-names>D</given-names></name></person-group><article-title>MicroRNA-183 suppresses neuropathic pain and expression of AMPA receptors by targeting mTOR/VEGF signaling pathway</article-title><source>Cell Physiol Biochem</source><year>2017</year><volume>41</volume><issue>1</issue><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1159/000455987</pub-id><pub-id pub-id-type="pmid">28214854</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Xie X, Ma L, Xi K, Zhang W, Fan D (2017) MicroRNA-183 suppresses neuropathic pain and expression of AMPA receptors by targeting mTOR/VEGF signaling pathway. Cell Physiol Biochem 41(1):181&#8211;192. 10.1159/000455987<pub-id pub-id-type="pmid">28214854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000455987</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J-J</given-names></name><name name-style="western"><surname>Kan</surname><given-names>Q-C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L-R</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y-Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z-Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z-S</given-names></name></person-group><article-title>Influence of CYP3A5* 3 polymorphism and interaction between CYP3A5* 3 and CYP3A4* 1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery</article-title><source>Eur J Anaesthesiol</source><year>2011</year><volume>28</volume><issue>4</issue><fpage>245</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1097/EJA.0b013e3283438b39</pub-id><pub-id pub-id-type="pmid">21513075</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Zhang W, Yuan J-J, Kan Q-C, Zhang L-R, Chang Y-Z, Wang Z-Y, Li Z-S (2011) Influence of CYP3A5* 3 polymorphism and interaction between CYP3A5* 3 and CYP3A4* 1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery. Eur J Anaesthesiol 28(4):245&#8211;250. 10.1097/EJA.0b013e3283438b39<pub-id pub-id-type="pmid">21513075</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Rao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kang</surname><given-names>X</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name></person-group><article-title>Progress, challenges, and prospects of research on the effect of gene polymorphisms on adverse reactions to opioids</article-title><source>Pain Ther</source><year>2022</year><volume>11</volume><issue>2</issue><fpage>395</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1007/s40122-022-00374-0</pub-id><pub-id pub-id-type="pmid">35429333</pub-id><pub-id pub-id-type="pmcid">PMC9098754</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Zhao J, Cai S, Zhang L, Rao Y, Kang X, Feng Z (2022) Progress, challenges, and prospects of research on the effect of gene polymorphisms on adverse reactions to opioids. Pain Ther 11(2):395&#8211;409. 10.1007/s40122-022-00374-0<pub-id pub-id-type="pmid">35429333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40122-022-00374-0</pub-id><pub-id pub-id-type="pmcid">PMC9098754</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><mixed-citation publication-type="other">Zhi-Xue L, Ye F, Wen-Yao L, Yan-Ping B, Yin-Chu C, Zai-Wei S, Rong-Sheng Z, Zhen-Yu R (2023) The effect of genetic variation on the sensitivity to opioid analgesics in patients with postoperative pain: an updated meta-analysis. Pain Physician <bold>26</bold>(5):E467. ISSN 2150&#8211;1149<pub-id pub-id-type="pmid">37774182</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>